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Neurodegenerative diseases are among the most devastating diseases for which there are no cure 
to date.  The greatest risk factor is advancing age. A common feature of these disorders is the 
toxic aggregation of a peptide particle. In Alzheimer’s, extracellular Aβ plaques are the 
pathological hallmark, while in Parkinson’s (PD), intraneuronal α synuclein inclusion bodies (Lewy 
bodies) mark pathology. This study will focus on the genetic approach to address open questions 
in these diseases which current genetic models have been unable to do. 
 
Although Aβ plaques are the hallmark of AD, the first asymptomatic stage precedes cognitive 
impairment by many years. Degeneration of the locus coeruleus (LC) is an early feature of AD. LC 
degeneration is preferential to rostral regions, which project to the cortex and hippocampus. 
These regions are also first affected in AD and are important for memory and learning. The LC 
nucleus has ubiquitous projections reaching all areas of the brain and providing the sole 
noradrenergic innervations to the cerebral, limbic and cerebellar cortices. LC has global functions. 
It is involved in general arousal, attention, vigilance and sensory processing, among others. The LC 
has also been implicated in cognitive functions such as synaptic plasticity, memory, adaptive gain 
and optimal task performance.  
 
Although many genetic AD mouse models exist, early LC cell loss is not recapitulated in these 
models. The exact contribution of LC loss to AD has remained elusive. Previous attempts to 
address this question, relied on either physical disruption of LC cells – through surgical 
intervention –, or the  used of the neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine 
(DSP-4) to chemically ablate LC cells. These procedures are invasive and unspecific. They can elicit 
compensatory responses to treatment and acute injury. We found a genetic approach to be more 
suitable to address the functional consequences of LC loss in AD pathogenesis and disease 
progression. To that end we crossed LC-deficient Ear2 (-/-) mice to double transgenic APP/PS1 
mice, a model for AD.  
 
We observed a 56% reduction in the number of Th(+) LC cells in Ear2 (-/-) mice, whether or not 
APP/PS1 were present. By 6 months of age, extent of plaque deposition seemed not affected by 
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NA deficiency. Noradrenaline (NA) levels correlated with the degree of LC innervation and 
APP/PS1 had no effect on NA levels. NA reduction in Ear2 (-/-) young mice was greatest in areas 
highly innervated by the LC. Olfactory bulb, frontal cortex and hippocampus lost 65, 53 and 70% 
NA, respectively. Cerebellum, with less LC input, lost 32%. APP/PS1 had no effect on NA levels. 
Regions most affected are important for memory and learning and affected in AD. The Morris 
water maze and electrophysiological recordings revealed a spatial learning and LTP impairment in 
both, Ear2 (-/-) as well as in APP/PS1 mice; but, the combination of these was most detrimental. 
LTP impairment was not associated to a short-term plasticity deficit and paired-pulse facilitation 
(PPF) was unaffected by NA reduction. Furthermore, the ratio of PPF remained unchanged before 
and after LTP, suggesting presynaptic terminals to be unaffected. Most importantly, cognitive 
impairments of Ear2 (-/-) were controlled by LC NA and treatment with the NA-agonist L-Threo 
DOPS restored cognitive functions. Under an AD-like background, the most detrimental cognitive 
impairment by NA deficiency and the partial restoration of cognitive function by supplementation 
of NA, argued for NA as a modifier of AD pathology. 
 
LC size was not affected by age or the chronic long-term deficiency of NA. NA reduction in aged 
Ear2 (-/-) mice was 76, 60, 75 and 51% in the olfactory bulb, frontal cortex, hippocampus and 
cerebellum, respectively. These represented higher losses that those seen at 3 months of age, 
indicating that chronic NA deficiency was accentuated with age. Comparing NA content of aged (1 
year) vs. young (3 mo) mice revealed no NA loss in wt mice, an approx. 25% NA decrease in Ear2  
(-/-) or APP/PS1 mice, and a NA reduction almost twice as large in the Ear2 (-/-)/APP/PS1. We 
concluded that in our wt mice there was no aging effect to NA levels in the brain. Long-term 
overexpression of APP/PS1 or long-term chronic NA deficiency seemed to deregulate the NAergic 
system. More importantly, the long-term chronic NA deficiency in a diseased environment is most 
detrimental to NAergic deregulation, which resembles early stages of AD. 
 
In conclusion, our model mimicked all features we have aimed to recapitulate. Specifically, we 
confirmed in our model at pre-plaque stages LC cell loss, decreased levels of NA, higher cognitive 
impairments and an AD-like phenotype that was reinforced with age. This features made our 
model a more suitable one to study early stages of AD pathogenesis and disease progression. In 
doing so, we found NA to be a disease modifying factor of AD-like pathology and we propose it to 




In PD, α-synuclein (SNCA) is the main component of Lewy bodies aggregating in neurons of the 
dopaminergic (DAergic) system in the brain. Existing models of PD and patients with duplications 
or triplications of SNCA have shown that PD is gene-dosage dependent. Current genetic SNCA 
models of PD are mostly based on overexpression. These models do not recapitulate all features 
of PD. For example, cell loss is not always achieved. Structural biology work and in-vivo testing has 
shown a mutant SNCA carrying three substitutions to a proline (TP-SNCA) to have reduced fibril 
formation, increased amounts of soluble oligomers and higher toxicity. Our aim was to generate a 
novel genetic model of PD to test the toxic properties of TP-SNCA in the mouse.  
 
Here we describe the cloning strategy used to generate the targeting vector of a new knock-in / 
knock-out, conditional mouse model that we termed SNCA to P3. These mice are engineered to 
express wt human SNCA in the endogenous mouse Snca locus in a conditional manner. Their 
progeny will switch to express TP-SNCA exclusively in the DAergic neurons, upon their mating to 
the DATcre line. Importantly, our model is not based on overexpression. By targeting the start 
codon of the murine gene, we disrupt its expression and utilize its endogenous promoter. This will 
ensure endogenous levels of expression of wt Human SNCA. Our model has spatio-temporal 
regulated expression of the mutant SNCA. This provides an additional level of specificity because 
expression of the toxic TP-SNCA will be directed and restricted to DAergic cells. So far, 2 positive 
ES cell clones have been identified and blastocyst injection will follow. The spatio-temporal and 
dosage-regulated expression makes our model a suitable one to study the toxic properties of TP-
SNCA. Additionally, the full value of our model relies on its potential to target different cell 





Chapter 1. Introduction 
 
Neurodegenerative disorders comprise a heterogenous group of chronic and progressive diseases 
such as Huntington’s, Parkinson’s, Alzheimer’s and Prion disease as well as tau pathologies [1]. 
These disorders are among the most devastating diseases for which we currently have not cure. A 
common feature in these disorders is the toxic aggregation of a protein particle and they are thus 
often referred to as aggregopathies. Except for Huntington’s disease, which is acquired in an 
entirely genetic manner, most aggregopathies are complex disorders occurring sporadically, but in 
some instances, are caused by inheritance of mutated genes [1]. This study will focus on the two 
most prevalent neurodegenerative disorders [2], namely Alzheimer’s disease and Parkinson’s 
disease. 
 
1.1. Alzheimer’s Disease 
1.1.1. Prevalence of the disease 
Alzheimer’s disease (AD) is a devastating, progressive and terminal neurodegenerative disease 
with no cure to date. AD results in a progressive decline of cognition and is the most common 
cause of dementia [3,4]. Over 36 million people are affected with dementia worldwide [5]. The 
greatest risk factor for AD is advancing age and most people affected with the disease are aged 65 
years or older [6]. Among the top 10 causes of death in the US, AD is number 6 [7]. AD is the only 
disease in the top 10 list that cannot be prevented, cured or even slowed [3]. Furthermore, while 
death rates for most major diseases have declined from 2000 to 2008, deaths from AD have risen 
by 66% [3]. In light of these alarming statistics, it is clear that AD has put an impressive 
economical and social burden on health care systems and societies around the globe. An aging 
population is on the rise and the economical burden of AD will continue to increase as well [6].  
 
 
1.1.2. Description of the disease 
AD causes the progressive loss of memory and other intellectual abilities. Symptoms include 
disorientation, confusion, mood and behavior changes, and difficulty in speaking, swallowing and 
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walking [8]. Disease progression is categorized into 7 stages by Dr. B. Reisberg [9]. The first stage 
(of no impairment) is completely asymptomatic and it is thought to begin 10 years or more before 
the patient first experiences any of the typical cognitive symptoms of AD [3,9]. Stages 2 and 3 
involve respectively, very mild and mild decline of cognitive functions [9]. Subsequent stages 
involve the progressive impairment from moderate to moderately severe to very severe decline 
(stages 4 to 7) [9]. A combination of mixed pathologies is common in older persons with dementia 
and at early stages of dementia it is difficult to discern them apart [10]. Mild cognitive impairment 
(MCI) is an established risk factor for AD. MCI is a condition in which essential cognitive abilities 
are impaired severely enough to be noticed by others and detected by cognitive testing, yet 
subjects are not demented, nor does this impairment affect the their daily life [3,11]. MCI is often 
considered the earliest clinical sign of probable AD because the pathological basis of MCI is similar 
to that of AD pathology [10].  
 
 
1.1.3. AD pathology 
Biochemically, AD pathology is characterized by the accumulation of senile plaques, 
neurofibrillary tangles, neuronal loss and changes in choline acetyltransferase activity [10,12]. 
Earliest damage in AD occurs in the entorhinal cortex, hippocampus and basal forebrain, which 
are regions with critical roles in memory [8,12] . Damage coincides with sites of plaque deposition 
[8,13].   
 
Senile plaques aggregate extracellularly and contain Amyloid-β (Aβ) amd neurofibrillary tangles 
that are intraneuronal aggregates composed of hyperphosphorylated forms of the microtubule-
associated protein tau [12,14,15]. These two – Aβ and tau – are the two hallmark proteins in AD 
[16]. Aβ is produced by the processing of the amyloid precursor protein (APP) through the 





1.1.4. APP processing pathways and mutations known to cause familial AD 
The amyloid precursor protein (APP) is a type I transmembrane protein consisting of 695- 770 
amino acids. Endoproteolytic and sequential cleavage of APP can occur through two distinct 
pathways to release either Aβ (amyloidogenic pathway), or p3, a non-pathogenic peptide (non-
amyloidogenic pathway) (as reviewed in [18,19,20], Fig. 1). Most APP is processed via the non-
amyloidogenic pathway, where the initial enzymatic cleavage is mediated by α-secretase. 
Cleavage by α-secretase occurs within the Aβ region and thus the formation of Aβ is precluded. 
The first cleavage results in the release of an extracellular, soluble APP fragment (sAPPβα) of ~110 
-120 kDa and a remaining C-terminal fragment of 83 amino acids in length (C83). Subsequently, 
C83 is cleaved by a γ-secretase enzyme complex to release a small, non-toxic p3 peptide (3 kDa) 
and a C-terminal fragment, the amyloid intracellular C-terminal domain (AICD). In the 
amyloidogenic pathway, APP is first cleaved by β-secretase. Cleavage by β-secretase releases an 
extracellular sAPPβ and the 99 amino acid-long C-terminal fragment (C99) is retained within the 
membrane. C99 is subsequently cleaved by a γ-secretase enzyme complex to release Aβ and AICD. 
 
The γ-secretase complex is formed by the enzymes presenilin-1 (PS1), presenilin-2 (PS2), nicastrin 









Fig. 1. APP processing pathways. Amyloid-beta (Aβ) is produced by the proteolytic cleavage of its 
precursor protein, the amyloid precursor protein (APP). APP is a type I transmembrane protein of 695- 770 
amino acid residues. APP can undergo two distinct processing pathways to release either the non-pathogenic 
p3 peptide (through the non-amyloidogenic pathway), or the Aβ peptide (through the amyloidogenic 
pathway). In the prevalent non-amyloidogenic pathway, APP is fist cleaved by α-secretase within the Aβ 
region, thus preventing its formation, and leading to the extracellular release of an α-cleaved, soluble APP 
fragment (sAPPα). Additionally, the remaining 83 amino acid-long carboxy-terminal fragment (C83) is 
further cleaved by the γ-secretase enzyme complex. This generates a small 3 kDa, non-toxic p3 peptide and 
an APP intracellular C-terminal domain (AICD). Alternatively, in the amyloidogenic pathway, the first 
enzymatic cleavage is mediated by β-secretase to release an ectodomain (sAPPβ) and retaining the 99 amino 
acid carboxy-terminal (C99) within the membrane. C99 is further cleaved by the γ-secretase enzyme complex 




Specific mutations in the APP or the PS1 genes are known to cause early-onset, familial AD. Some 
of the mutations, segregating in an autosomal dominant fashion, have been exploited in the 
generation of genetic models to mimic AD pathology. 
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In the APP gene, among the most frequently used mutations to generate transgenic models of AD 
are the Swedish and London mutations. The former refers to two missense mutations just prior to 
the Aβ N-terminus at positions 594 and 595 substituting K → N and M → L, respectively, found in 
a family of Swedish origin [22]. The latter refers to the V717I substitution found in a family of 
British origin [23]. 
 
In PS1 many mutations concentrate in and around the transmembrane regions of the protein 
[24,25,26]. Transgenic AD models carrying mutated versions of the PS1 gene often target 
mutations shown to produce a most aggressive AD-like phenotype. 
 
Mutations in the APP, PS1 and PS2 genes account for most of the familial early-onset cases of AD 




1.1.5. Neuronal loss and degeneration of the Locus Coeruleus  
Another pathological feature of AD is neuronal loss. Post-mortem analysis of definitive AD brains 
has shown extensive neuronal loss in cortical and hippocampal regions and in the noradrenergic 
nucleus Locus Coeruleus (LC)[4,28,29]. LC cell numbers are reduced by approx. 55% in AD and 
78% in Parkinson’s disease patients [29]. LC loss results in decreased noradrenaline (NA) levels in 
the forebrain regions in AD [4,13,30,31,32]. Furthermore, reduction of NA in the cortex [4] or LC 
cytophathology [33] in AD brains correlates with cognitive impairment. Additionally, LC loss 
correlates with disease duration [29,34] and severity of cognitive decline [35]. 
 
Although LC loss exists in both Alzheimer’s and Parkinson’s disease (PD), there are disease-specific 
patterns of LC cell loss. Cell loss in PD ranged from 30 to 90% in the mildest and most severe 
instances, respectively. Notably, the pattern of cell loss followed a rostral to caudal fashion [29]. 
In AD, however, the extent of cell loss was positively correlated to the duration of dementia 
[29,34]. Patients with a 1.5 to 2 years history of dementia had a 48 to 69% LC cell loss, while 58 to 
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89% LC cell loss was observed for brains of patients with 3 to 8 years of dementia. Most 
demented patients lost 81 % LC cells, whereas least demented ones exhibited <20% cell loss. The 
pattern of LC cell loss in AD was greatest rostrally, and caudal LC cells seemed to be spared [29]. 
Rostral LC neurons project to the cortex, hippocampus and forebrain, while ventrocaudal neurons 
innervate the spinal cord and cerebellum preferentially. In AD, there seems to be a sparing of cells 
projecting to the latter regions [29]. Notably, former regions are relevant for learning and 
memory and initially also most affected by plaque deposition in AD. 
 
Importantly, degeneration of the LC has been detected at early stages of AD [29,33]. Emerging 
data present evidence for LC loss to begin several years to decades before the clear manifestation 
of cognitive impairments and dementia [36,37]. Thus, LC degeneration has been proposed as an 
early feature of MCI or AD and as a factor mediating the onset of cognitive impairment [33,38]. 
Treatment after definitive plaque deposition might be too late in the pathogenic process of AD for 
an agent to revert the effects of a long-term toxic environment to any significant level. It is thus 
important to investigate early stages of AD. These are potentially the most promising phases to 
develop successful strategies to manage and treat AD. Not surprisingly, pharmaceutical 
companies and research consortia, like the AD Cooperative Study, are focusing on MCI patients 
for large treatment trials [11].  
 
Toxin-induced degeneration of LC neurons exacerbates AD pathology in models of AD providing 
evidence for the involvement of LC loss in AD progression. Selective ablation of LC neurons with 
the neurotoxin DSP-4 in mouse models of AD promoted pathogenesis by increased glial 
inflammation, amyloid plaque deposition, cortical and hippocampal neurodegeneration, and 





1.1.6. Description of the Locus Coeruleus 
1.1.6.a. Anatomical description of the Locus Coeruleus 
The LC is a nucleus located in the dorsal pons [40]. Immunohistochemical and computer-aided 
three dimensional reconstructions of the adult human LC show it as a continuous column of 
approximately 15 mm in length, extending rostrocaudally in the upper lateral pontine central gray 
[41,42,43]. The LC nucleus of young adult humans is composed of 45 000 to 65 000 neurons 
[29,42,44]. 
 
The concept of an aging component to reduce the number of LC cells through life is slowly more 
accepted; however, reports are still inconclusive. In humans, using computer-assisted mapping of 
immunoreactive neurons and three-dimensional reconstruction the number of LC neurons 
declines by 25% with age [13,44]. NA concentration was reduced between the fourth and ninth 
decades in humans [13]. However, using unbiased stereological methods, no change in cell 
number or size is seen in the LC of older as compared to young individuals [45]. Methodological 
differences, exact delineation of LC proper cells and the assumption-based nature of conventional 
sampling and estimation techniques have been suggested as possible explanations for the 
discrepancy. In rats, Hervonen and colleagues have analyzed the LC of young and aged rats in 
several occasions and found no LC cell loss due to age [46,47,48].  
 
1.1.6.b. Projection areas of the Locus Coeruleus 
The LC is a unique nucleus in that is has the most divergent and ubiquitous projections 
throughout the central nervous system [43]. LC projections reach almost every region of the brain 
(Fig.2), with the exception of the basal ganglia [49]. While other noradrenergic cell groups exist, 
the LC (cell group A6) is considered to be the main NA producer in the brain [13,49,50]. LC 
neurons provide the sole noradrenergic innervation of the cerebral, limbic and cerebellar cortices 
[43]. LC projections reach all cerebral cortices. Among the thalamic nuclei and limbic structures 
receiving input from the LC are the amygdala, hippocampus and septum. LC efferents innervate 
also the brainstem [13,49]. Through a high degree of axonal branching single neurons from the LC 
can innervate multiple regions that are remotely located within the brain, from cortex to brain 
stem or cerebellum [29,49].   
15 
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Fig. 2. Schematic representation of locus coeruleus (LC) noradrenergic projections. The LC (A6), 
located in the dorsal pons, is the main brain source of noradrenaline (NA) projecting mainly to the ipsilateral 
forebrain. LC projects to the entire cortex. Also, thalamic nuclei and limbic structures, including the 
amygdala, hippocampus and septum receive LC projections. Owing to their highly axonal branching, a single 
LC neuron can innervate multiple brain regions that are distant from one another. Notably, the only region 
devoid of LC input is the basal ganglia. Abbreviations: AON, anterior olfactory nucleus; AP-VAB, ansa 
peduncularis–ventral amygdaloid bundle system; BS, brainstem nuclei; C, cingulum; CC, corpus callosum; 
CER, cerebellum; CTT, central tegmental tract; CTX, cortex; DB, dorsal bundle; DPS, dorsal periventricular 
system; EC, external capsule; F, fornix; FR, fasiculus retroflexus; H, hypothalamus; HF, hippocampal 
formation; ML, medial lemiscus; MT, mamillothalamic tract; OB, olfactory bulb; PT, pretectal area; RF, 
reticular formation; S, septum; SC, spinal cord; ST, stria terminalis; T, tectum; TH, thalamus. Modified from 
Sara, 2009, Nat Rev Neuroscience. 
 
 
1.1.6.c. Functional description of the Locus Coeruleus 
Because of its ubiquitous projections, the LC has been proposed to have global functions [29]. The 
LC is involved in general arousal, attention, stress, anxiety, affective disorders, vigilance, and 
sensory processing, [as reviewed in [30,49,50]]. It has also been implicated in cognitive functions 
including synaptic plasticity, memory, decision making, performance facilitation, adaptive gain 
and optimal performance [as reviewed in [49,51]]. Pharmacological studies have provided 
evidence for LC NA to modulate memory formation (through input to the amygdala and 
hippocampus) and in attention and working memory functions (through frontal cortex 
innervations). Likewise, electrophysiological analyses of LC neurons show a clear relation between 




1.1.6.d. Neurochemical description of the Locus Coeruleus 
Most LC neurons synthesize and transport NA. Although, NA is best known for its function as a 
classical neurotransmitter, locally diffusing NA also has anti-inflammatory properties by negatively 
regulating the transcription of inflammatory genes in astrocytes and microglia. [52]. Inflammation 
has been extensively linked to AD pathology because Aβ toxicity to cells is mediated by 
neuroinflammation, among several other mechanisms[53]. Furthermore, Aβ is known to activate 
the classical pathway complement cascade [54]. Congruently, sites of Aβ plaque deposition are 
also sites where inflammation is detected [35]. We have recently shown that toxin-induced 
degeneration of the LC induced inflammation and contributed to reduce Aβ clearance [55].  
 
Although the LC is considered the main source of NA in the brain, LC cells do not synthesize NA 
exclusively. Subsets of LC neurons produce and transport also other neuromodulators. Among 
those are brain-derived neurotrophic factor (BDNF) [56], neuropeptide Y (NPY) [57], galanin [57], 
enkephalin and cocaine-and amphetamine-regulated transcript (CART) [58]. 
 
Our lab had previously generated the Ear2 knock-out mutant mouse [59]. Under a genetic hybrid 
background, adult Ear2 (-/-) mice lack more than 70% LC neurons. Agenesis is preferential to the 
dorsal division of the LC, which projects to cortical areas [59]. Ear2 (-/-) mice develop otherwise 
normal, are born alive and are fertile. Other features of Ear2 mutant mice are deregulation in 
circadian rhythmicity and impaired nociception [59]. 
 
 
1.1.7. Current genetic mouse models of AD 
With molecular biology becoming a standard procedure, many genetic murine models of AD 
became available within the last few decades. As previously discussed (see section: “APP 
processing pathways and mutations known to cause familial AD” above), most genetic models 
have attempted to mimic the disease using mutations known to cause early-onset familial AD. 
Most of these mutations [27], and thus genetic models, involve the APP, PS1, PS2 and tau genes 
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either alone or in combination [30]. However, other AD-associated genes have also been used in 
the creation of novel models seeking to recapitulate the disease more faithfully. Among these, 
models involving ApoE, tau protein, BACE (γ secretase) or TGF-β1 (a cytokine) are available *for 
review see [60]].  
 
A wealth of genetic mouse models exists to date. There are for example knock-ins, knock-outs, 
single-, double- or triple mutants. And many models now carry a combination of two or more 
variant genes. The overwhelming majority of genetic models available are transgenic. Typically, a 
mutant variant of the gene(s) is under the expression control of a neuronal-specific strong 
promoter, the prion protein (PrP) or Thy1 promoters are examples, to drive elevated and directed 
expression of the transgene(s).   
 
Among the many models available, most transgenic APP mice carry the Swedish mutation, alone 
or in combination with different mutations in PS1. For example, the APP/PS1KI model expresses a 
human APP (751 amino acids long) with the Swedish and London mutations together with 2 
mutations in PS1 (M233T and L235P). APP is under the control of a Thy1 promoter and PS1 under 
the endogenous mouse PS1 promoter (knock-in)[61,62]. Although these mice seem normal at 2 
months of age, at the age of 6 months a dramatic, age-dependent manifestation of AD-like 
features begins. These include Aβ plaque deposition, impairment in working memory and motor 
tasks, brain and spinal cord axonal degeneration and hippocampal CA1 cell loss [62,63]. The 
Tg2576 model carries the Swedish mutation in a human APP under the PrP promoter [64]. These 
mice develop Aβ plaques and show spatial and working memory impairments when tested in the 
Y-maze and the Morris water maze at 9 months of age [64]. Additionally, synaptic plasticity is 
selectively impaired as LTP recordings in the Schaffer collateral pathway, but not the mossy fiber 
pathway, was completely abolished [65] . Transgenic 5xFAD harbor 3 mutation in the APP gene 
and two in PS1 gene and accumulate plaques  very early in life, typically by 4 to 5 weeks of age 
[66]. These mice show high neuronal damage and cognitive deficits by 5 months of age [66]. The 
5xFAD model is one of the few models showing LC damage and inflammation [67]. However, this 




Current models of AD have been very useful tools to investigate the consequences of extensive 
Abeta plaque deposition and its regulation [13]. For example, they have demonstrated that 
plaques have a primary role in AD neuronal loss [68]. They have also served to assess potential 
therapeutic interventions [13]. However, they have yet to recapitulate some major anatomical 
pathology, and biochemical and behavioral features [13]. Very few in vivo studies have 
investigated the role of noradrenergic mechanisms in APP-related processes [13]. Furthermore, 
current AD mouse models do not recapitulate early LC degeneration in AD [30]. Specifically, LC 
neuronal loss or lower NA levels in the brain of genetic AD models have not been shown at pre-
plaque stages. LC cell death or damage has been reported only in a few lines and only months 
after plaque deposition has set in [67,69,70]. 
 
 
1.1.8. Description of the AD model used in this study, APP/PS1 double transgenic mice 
A well-established AD mouse model is the double transgenic Mo/HuAPP695Swe/HuPS1-ΔE9 
mouse. This line carries mutant variants of APP and PS1 as transgenes. The mouse APP transgene 
is the 695 amino acid-long transcript variant with a humanized sequence within the Aβ fragment. 
The APP transgene also carries the Swedish mutation (K594N/M595L), known to increase Aβ 
production and to cause early-onset AD [71,72]. The PS1 transgene is a human PS1 that lacks exon 
9. The splice-site mutation leading to the in-frame skipping of exon 9 is associated with early-
onset AD [25] .Bigenic mice overexpress APP and PS1, and develop Aβ plaques by 6 months of 
age. The expression of each transgene is controlled by a mouse prion protein promoter element. 
Because the two transgenes co-integrated into the same locus, they co-segregate as a single 
locus. These mice (from here on only referred to as APP/PS1) were first reported by Jankowsky et 
al. in 2001 [73]. APP/PS1 mice were used in this study and were kindly provided to us by Dr. 




1.1.9. Aim of work, objectives and hypothesis  
 
Transgenic models have been extremely helpful tools and beneficial in the study of AD [60,62]. 
Although many faithfully recapitulate certain features of AD, such as Aβ plaque deposition, brain 
inflammation, hyperphosphorylated tau and memory impairments, they fail to mimic others [30]. 
For example, LC cell loss is not observed in these mice, although its involvement to AD pathology 
in humans is well established [30,38]. The exact contribution of LC loss to the pathology of AD is 
yet to be elucidated. 
 
Currently, we rely on chemical or surgical methods to ablate LC neurons in transgenic AD models 
at pre-plaque stages. N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) has been 
established as the preferred noradrenergic neurotoxin to target LC neurons [38,39,74,75,76]. 
These models have been a useful tool; however their specificity to noradrenergic neurons and the 
validity of their results (as affected by compensatory mechanisms to surgical lesions) have been 
questioned [75,76,77]. More refined, novel genetic models mimicking LC loss will allow us to 
investigate the exact contribution of LC loss to AD pathogenesis and progression of the disease. 
 
We aimed to address this question by generating a new AD model of early stages. We wanted our 
new model to mimic cognitive impairment, LC neuronal loss and lower brain NA levels, preceding 
plaque deposition. To that end, we crossed LC-deficient Ear2 (-/-) mice to the well-established 
APP/PS1 double transgenic model of AD. We confirmed that our new model mimics all features 
we aimed to recapitulate. This made our model a more suitable one to study the early stages of 






1.2. Parkinson’s Disease 
1.2.1. Prevalence of the disease 
Parkinson’s Disease (PD) is a progressive and chronic neurodegenerative disease associated with 
motor symptoms [78]. PD affects 1.5% of the global population over 65 years of age [78] and it is 
the second most prevalent neurodegenerative disorder [2]. In the European Union, more than 
500 000 people are estimated to suffer from the disease [2]. Furthermore, no cure exists to date 
for PD. Currently, only a symptomatic therapy is available. Symptoms can be improved by 
pharmacotherapy, including levodopa, dopamine receptor agonists or monoamine oxidase B 
inhibitors, or through surgical strategies, such as deep brain stimulation for patients with severe 
motor fluctuations [78].  
 
 
1.2.2. Description of the disease 
There are four cardinal symptoms of PD, namely bradykinesia, rest tremor, rigidity and postural 
instability [79]. Additional PD motor features include loss of automatic movements, such as arm 
swing, loss of blinking, reptile stare and difficulty to perform two simultaneous motor tasks [79]. It 
is increasingly recognized that non-motor symptoms are also an integral part of the disease[2]. 
These include autonomic and cognitive impairments. Among the former disturbances are 
constipation, hypotension, urinary frequency, impotence and sweating [79]. Among the latter 
impairments are hallucination, delusion, dementia, behavioral abnormalities, depression, sleep 
disturbances and loss of smell and pain sensation [78,79].  
 
 
1.2.3. PD pathology and brain regions affected 
Biochemically, PD pathology is characterized by the aggregation of eosinophilic intraneuronal 
inclusions of various shapes and subcellular locations [2,79]. These are called Lewy bodies and 
Lewy neurites after their first description in 1912 by the German neurologist Friedrich H. Lewy 
[80].  Lewy bodies and Lewy neurites consist mainly of fibrillar α-Synuclein [2]. Lewy body 
inclusions is the pathologic hallmark of PD; while the anatomical hallmark is the relatively 




Neuronal loss and Lewy body formation are also present elsewhere. Additional sites of Lewy body 
deposition are: LC, pedunculo-pontine nucleus, raphe nucleus, dorsal motor nucleus of the vague 
nerve, olfactory bulb, parasympathetic and sympathetic post-ganglionic neurons, Meynert 
nucleus, amygdaloid nucleus and cerebral cortices [79]. Non-motor symptoms of PD are caused by 
lesions to these nuclei and regions other than the SN [79]. And motor deficits are thought to be 
the consequence of the predominant degeneration of dopaminergic neurons of the SN [2]. The SN 
is also affected in all parkinsonian conditions, not only in PD [43]. Parkinsonian conditions include, 
for example, dementia with Lewy bodies, progressive supranuclear palsy and multiple-system 
atrophy.  
 
The mesencephalon contains the two major dopaminergic cell groups, cell group A9 (substantia 





      
             
Fig. 3. Schematic representation of the dopaminergic nuclei, substantia nigra and ventral tegmental area and 
their projections. The substantia nigra (SN, A9) projects to the striatum. The ventral tegmental area (VTA, 
A10) is the main cortical input of the dopaminergic system, which is limited to the frontal regions, entorhinal 
cortex (EC) and piriform cortex (PC). Abbreviations: A, amygdala; ACC, anterior cingulate cortex; AON, 
anterior olfactory nucleus; CC, corpus callosum; FC, frontal cortex; OB, olfactory bulb; OT, olfactory tract; 




The substantia nigra (SN, cell group A9) encompasses the most ventral part of the entire midbrain 
tegmentum, just dorsal to the cerebral peduncles [43,82]. Nigral neurons project mainly to the 
striatum along the nigrostriatal pathway [82]. The SN plays a major role in the control of actions 
and thoughts and it has been extensively involved in addiction and addictive behavior 
[50,83,84,85,86]. 
A10 neurons of the vental tegmental area (VTA) project mainly to limbic and cortical areas along 





1.2.4. Snca gene locus 
α-Synuclein (SNCA) is the major structural component of Lewy bodies and Lewy neurites. It is a 14 
kDa protein whose primary function has remained elusive, but that is expressed abundantly in 
presynaptic terminals of regions displaying synaptic plasticity [87,88].  
 
Based on its expression site, on reported SNCA’s association to vesicles and on the phenotype of 
genetic models, SNCA has been proposed to play a role in intracellular trafficking and to regulate 




Fig. 4. Schematic representation of the α-synuclein gene. Functional domains of SNCA. Mutations known 
to cause familial early-onset PD are marked in black, while structure-based design mutants are in red. TP-
SNCA contains all three substitutions to a proline residue at positions 30, 56 and 76 (below the sequence). 
Regions involved in β-sheet formation are in purple. The central non-amyloid component (NAC) region is 
critical for SNCA aggregation. Modified from Karpinar et. al., 2009, EMBO J. 
 
 
The primary sequence of SNCA is 140 amino acids long and it has been fairly well characterized. 
Three distinctive regions are present. The amino-terminal, characterized by imperfectly conserved 
repeats, acquires α-helical structure upon lipid binding, while the carboxy-terminal is highly 
flexible [89]. The central hydrophobic region, called the non-amyloid component (NAC), is 




SNCA normally exists in an unstructured state [81]. However, it can also form oligomers, 
protofibrils, fibrils and filaments [90]. Stabilization of these higher-ordered structures may be 
central to the pathogenesis of PD [81]. Genome-wide association studies identified SNCA as a 
major risk locus for PD across global populations [91]. 
 
 
1.2.5. Mutations known to cause familial PD 
Mutations in SNCA are known to cause familial early-onset PD. The missense mutation A53 was 
the first to be identified. Two additional mutations have subsequently followed, the A30P in a 
German kindred and the E46K in a Spanish family [2]. These mutations show an increased 
propensity for misfolding, and this appears to play a prominent role in cell death [81]. PD-causing 
mutations also enhance SNCA protofibril formation [88]. In genetic mice models, both the A30P 
and A53T (singly or in combination) cause increased SNCA inclusions, neurotoxicity and a motor 
phenotype [92,93]. To date more than a dozen loci and genes have been associated with PD. 
 
Gene dosage has also been associated with PD and multiplications of the wild-type SNCA cause 
PD. A dose dependency is demonstrated by the earlier age of onset (35 years in average) and high 
PD prevalence in patients carrying SNCA triplications compared to patients carrying SNCA 
duplications, who show a more typical late-onset PD phenotype [2]. Likewise, overexpression of 
human SNCA in mice results in neurophathological and behavioral phenotypes that are 
proportional to the expression level [94]. 
 
A similar scenario as for genetic models of Alzheimer’s disease occurred in the PD field. The basis 
for the creation of numerous genetic mouse models was the identification of mutations known to 
cause PD. Mutations inherited in an autosomal dominant fashion that are 100% penetrant and 





1.2.6. Current models of PD 
There are many mouse models of PD available to date. Many follow the classical neurotoxin-
based approach to selectively ablate dopaminergic cells. Others have been genetically modified to 
abolish expression of key PD-associated genes. There is also a wide collection of tissue-specific 
mutants, targeting mainly the dopaminergic system and using one or more of the PD-causing 
SNCA mutant variants, or the over expression of its wild-type version. 
 
Toxin-based models typically using 6-hydroxydopamine (6-OHDA) or  1-methyl-4-phenyl1-1,2,3,6 
tetrahydropyridine (MPTP) target the dopaminergic system [95]. These models have been of great 
value to understand the consequences of nigrostriatal dopaminergic cell loss and to test 
symptomatic therapies [96]. However, drawbacks of these models are their considerable 
limitations for assessing disease-modifying and neuroprotective treatments [78]. 
 
Most of the genetically modified mice include knock-outs and transgenics. Among the knock-out 
lines, SNCA itself and many PD-linked genes (identified as susceptibility genes) have been created. 
For example, Snca (-/-) mice show reduced rearing activity in the open field, have decreased 
striatal dopamine levels and a decreased reserve pool of vesicles in the hippocampus [87,94]. 
None of the genetic models based on PD-linked genes mimic the key symptoms of the disease to 
their full strength; they show rather a more subtle effect on the dopaminergic system [95]. 
Dopamine levels in striatum, motor disturbances or abnormal response to dopamine agonists are 
only slightly altered.  
 
Transgenic SNCA lines, on the other hand, have mimicked more PD-like symptoms. Many single 
and combinatorial transgenic lines exist to date. Owing to SNCA’s prominent role in PD and 
related synucleinopathies, many SNCA transgenic mice have been created and characterized [for 
review see [81,93]]. Many new SNCA transgenic mice became available between 2000 and 2005. 
Most reports included a wt human SNCA and the A53T mutant variant, either alone or in 
combination with A53T. Promoters used were mainly the murine Thy-1 promoter, mouse or rat 
Prion Protein (PrP) promoter or rat TH. All transgenic models were based on overexpression. A 
very broad range of overexpression was detected depending on the promoter used, with the PrP 
driving a 2.5 to 30-fold expression increase and the Thy-1 promoter an approx. 10-fold 
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overexpression. Most transgenic mice show SNCA inclusions and some also have lower dopamine 
levels. A motor phenotype was also present in most of these models.  
 
Although genetic models have more successfully recapitulated some pathological features of PD, 
such as presence of Lewy bodies or Lewy neurites and motor deficits, they have fallen short in 
others. For example, cell loss is not always achieved and non-motor symptoms are either absent 
or not analyzed. To date, no single model created for PD reproduces all key symptoms of the 
disease  [95] and there is a need for more refined animal models [78]. 
 
Importantly, genetic models are based on overexpression of a wild-type or mutant variant. This 
experimental design does not allow for the investigation of the pathology caused by a specific 
mutation or the mechanism of its toxicity. In overexpresion-based models phenotypes observed 
can be the result of the particular mutation or the overexpression itself. 
 
 
1.2.7. Increased toxicity of TP-SNCA soluble oligomers, not fibril-aggregates 
Reports in several model systems find no correlation between the rate of fibril and inclusion 
formation and neurotoxicity [97,98,99,100]. To reconcile these findings, researchers posited that 
small oligomers of SNCA, rather than fibrils, are the toxic species in PD [101]. Recently, Karpinar et 
al. showed through extensive biophysical analysis and testing in in-vivo systems that TP-SNCA has 
reduced fibrillization propensity [100]. In addition, TP-SNCA forms increased amounts of soluble 
oligomers, has higher neuronal toxicity and elicits behavioral defects [100]. Through solid-state 
NMR analysis, aggregates of TP-SNCA and SNCA-A56P have an impaired β-structure formation, 
showing strong dynamics/disorders. In vivo, TP-SNCA was also shown to be unable to form fibrils 
in HEK cells, mammalian primary cortical neurons, C. elegans and Drosophila melanogaster [100]. 
In the latter two, TP-SNCA impaired dopamine-related behavior, which is relevant and affected 




1.2.8. Aim of work, objectives and hypothesis 
 
Our objective was two-fold. First, we aimed to fill the need for a more fine-tuned and faithful 
model to recapitulate Parkinson’s disease. Second, we wanted to confirm in-vivo in a mammalian 
system the neurotoxicity of a fibril-deficient Synuclein carrying three Ala->Pro substitutions at 
positions 30, 56 and 76 (triple-proline substitution SNCA, TP-SNCA). We cloned a targeting vector 
to generate a knock-in/knock-out conditional TP-SNCA mouse. The new TP-SNCA line will express 
a floxed-wild-type human SNCA under the endogenous mouse Snca promoter. By targeting the 
start codon, we disrupted the endogenous murine Snca and utilized its promoter to drive 
endogenous levels of expression of the wild-type human SNCA. We created thus, a model not 
based on overexpression. Upon crossing of our mouse to the DATcre line, progeny will switch to 
express TP-SNCA in cells of the dopaminergic system exclusively. This will provide an additional 
level of specificity because the mutant variant of SNCA and its toxic effects will be directed and 
exclusively restricted to the areas affected in PD patients. In theory, this spatio-temporal and 
dosage-regulated expression will make our model excel from already existing ones. Following a 
characterization of the model, our new model will provide a more specific system to investigate 
the toxicity of TP-SNCA because it is not based on overexpression. We generated the targeting 
vector, and ES cells were electroporated. So far, successful targeting has been identified in two ES 




Chapter 2. The contribution of noradrenaline to the pathogenesis and 
disease progression of Alzheimer’s disease 
 
2.1. RESULTS 
2.1.1. Generation of a new genetic Alzheimer’s disease mouse model 
In an attempt to better mimic the degeneration of the Locus Coeruleus (LC) and reduction of 
noradrenaline (NA) levels seen at the early, pre-plaque stage of Alzheimer’s disease (AD), we 
generated a new genetic AD mouse model.   
 
We used mice lacking the Ear2 gene, which had a reduced LC in a mixed genetic background [59], 
and we backcrossed these to a pure C57B/6N genetic background for at least 7 generations. 
C57B/6N Ear2 mutants were then crossed to APP/PS1 mice, a double transgenic AD model 
expressing mutant versions of APP and PS1. To our knowledge, the Ear 2 (-/-)/APP/PS1 mouse is 
the first genetic mouse model of AD mimicking the LC reduction at pre-plaque stages of the 




2.1.2. Validation of a reduced LC in the new AD model Ear2 (-/-)/APP/PS1  
In order to validate the original phenotype of an Ear2 deletion, namely the reduction of the LC, 
we analyzed the LC size in the newly generated Ear2 (-/-)/APP/PS1 and in control mice. 
 




In situ hybridization (ISH) with the LC marker tyrosine hydroxylase (Th) confirmed a reduced LC in 
Ear2 (-/-) whether or not APP/PS1 were present (Fig. 5). A digoxigenin-labelled Th probe identified 
the LC nucleus in serial coronal sections of 3-month-old mice (Fig. 5A). Fewer Th(+) cells could be 
observed in Ear2 (-/-) than in wild-type mice. Cell density was also lower in these animals (Fig. 5A). 
Sections from APP/PS1 mice were indistinguishable from those of mice not carrying the 
transgenes. That is, APP/PS1 mice appeared to have as many Th(+) cells as wild-type mice. 
Analogously, sections from Ear2 (-/-)/APP/PS1 and Ear2 (-/-) mice lacked Th staining to the same 
extent. Quantification of Th(+) cells demonstrated the drastic reduction of positive Th cells in 
Ear2(-/-) mice (Fig. 5B). Wild-type mice had an average of 1435.2 (±159.5) Th(+) cells per LC (n=6). 
The number of Th(+) cells in APP/PS1 mice was slightly reduced, 1255.7 (±70.9) cells per LC (n=6). 
However, cell numbers were greatly reduced in Ear2 (-/-) mice, whether or not APP/PS1 were 
present. Respectively, Ear2 (-/-) and Ear2 (-/-)/APP/ PS1 mice had 624.5 (±48.6) and 625.2(±46.4) 
Th(+) cells per LC (n=6 each genotype). These results were corroborated with a second LC marker, 
Dbh (Dopamine beta hydroxylase; data not shown).  
 
Overall, Ear2 (-/-) mice showed a 56 % reduction in the number of Th(+) cells. The presence of 







Fig. 5. Validation of a reduced Locus Coeruleus (LC) in the new AD model, Ear2(-/-)/APP/PS1. Ear 2 
(-/-) mice had 56% less Th(+) LC cells and APP/PS1 did not drastically affect LC size.  A) Anatomical 
location of the LC nucleus in a coronal view. Bregma -5.40mm. Modified from Franklin and Paxinos, 3
rd
 ed. 
[40]. In-situ hybridization of coronal sections of 3 month old mice. Tyrosine hydroxylase (Th) probe 
identifies LC cells. Ear2 (-/-) mice showed markedly reduced Th staining compared with Ear2 (+/+) control 
mice. LC cells from Ear2 (-/-) mice seemed scarcer and less dense. Th staining in APP/PS1 mice resembled 
that of Ear2 (+/+).  B) Quantification of Th(+) cells showed a slight decrease in Th(+) cell number in the 
Ear2 (+/+)/APP/PS1 and a drastic 56% reduction of LC cells in Ear2 (-/-) with or without APP/PS1. *p < 
0.05; ***p < 0.001; n=6 each genotype. Error bars indicate s.e.m. 
 
 
These data confirmed the reduction of the LC in Ear2 (-/-) in a pure C57B/6N background and in 
the presence of APP/PS1. Albeit somewhat attenuated, the drastic significant LC reduction 
detected here is in agreement with the phenotype originally reported by Warnecke et. al. [59]. 
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APP/PS1 mice have slightly less LC neurons, indicating that up to this stage APP/PS1 have no 
drastic effects on LC size.  
 
 
2.1.3. Analysis of plaque deposition at 6 months of age 
In order to investigate whether chronic NA deficiency, and thus deficiency of NA’s anti-
inflammatory properties, impacted plaque deposition, we stained Abeta plaques. 
 
Fluorescent microscopy was used to identify Abeta plaques stained with Thioflavin S. Sets of 
representative sagittal sections throughout the brain of 6-month-old mice were used. Sections 
from Ear2 (+/+)/APP/PS1 and Ear2 (-/-)/APP/PS1 mice were indistinctive from one another in both 





Fig. 6. Thioflavin S staining of Abeta plaques in the hippocampus and cortex. Plaque deposition was 
the same in the hippocampus and cortex of Ear2 (+/+)/APP/PS1 and Ear2 (-/-)/APP/PS1. Sagittal 
sections of 6-month-old Ear2 (+/+)/APP/PS1 and Ear2 (-/-)/APP/PS1 were stained with thioflavin S to mark 
Abeta plaques and subsequently analyzed by fluorescence microscopy.  Thioflavin S staining of Abeta 





Abeta plaque staining was identical for mice with or without a chronic reduction of NA. Sections 
from Ear2 (+/+)/APP/PS1 and Ear2 (-/-)/APP/PS1 mice had the same plaque load in both the 
hippocampus and cortex. Plaque deposition seemed, at least up to 6 months of age, unaffected 
by the lack of NA. 
 
 
2.1.4. Quantification of NA levels throughout the brain in young mice 
In order to assess whether a reduced LC translated into lower NA levels throughout the brain, we 
measured NA concentration in the olfactory bulb, hippocampus, frontal cortex and cerebellum. 
The former three are regions with high LC innervation and are relevant for learning and memory. 
The cerebellum was included as control because it is less innervated by the LC but it is not 
implicated in memory.  
 
This work was carried out partly in collaboration with Inga Urban. 
 
HPLC was used to quantify NA concentration in brains of 3-month-old mice (Fig. 7). In the 
olfactory bulb, NA concentration in wild-type was 0.3586 (±0.026) ng/mg of tissue, while Ear2 (-/-) 
had only 0.1252 (±0.021) ng/mg of tissue (Fig. 7A). The frontal cortex of wild-type mice contained 
0.4636 (0.022) ng/mg of tissue. And NA dropped to 0.219 (±0.052) ng/mg of tissue in the Ear2 (-/-) 
(Fig. 7B). Similarly, NA concentration in the hippocampus was 0.532 (±0.045) ng/mg of tissue and 
only 0.16 (±0.036) ng/mg of tissue in Ear2 (+/+) and Ear2 (-/-), respectively (Fig. 7C). A strong 
reduction of NA was also detected in the cerebellum, where wild-type mice contained 0.5276 
(±0.053) ng/mg of tissue and Ear2 (-/-) 0.3597 (±0.028) ng/mg of tissue (Fig. 7D). Throughout the 
brain, NA levels of APP/PS1 mice were comparable to those of mice not carrying the transgenes 









Fig. 7. HPLC quantification of noradrenaline (NA) concentration in the brain. Reduction of the LC 
resulted in lower noradrenaline levels throughout the brain. Areas with high LC innervations were 
most affected.  A) NA loss in the olfactory bulb of Ear2 (-/-) and Ear2 (-/-)/APP/PS1 mice. Ear2 (-/-) mice 
showed a 65.1% loss of NA. Mice carrying APP/PS1 had similar levels of NA to those mice negative for the 
transgenes.  B) In the frontal cortex, Ear2 (-/-) mice lost 52.8% of NA compared to wild-type mice. The 
presence of APP/PS1 had no effect on NA concentration.  C) NA levels in the hippocampus of Ear2 (-/-) 
mice had a drastic reduction of 70%. APP/PS1 had no impact on NA levels in the hippocampus either.  D) 
NA levels in the cerebellum of Ear2 (-/-) mice were reduced by only 31.8%, albeit still extremely significant. 
APP/PS1 positive or negative mice had comparable levels of NA. Compared to wild-types, the cerebellum of 
Ear2 (-/-) mice lost about one third of their NA level, whereas all other regions lost more than half. NA levels 
were affected by Ear2 exclusively and not by APP/PS1. Levels of NA loss correlated with the degree of LC 
innervation in the respective brain area. Hippocampus, frontal cortex and the olfactory bulbs are regions with 
high LC innervations and are also relevant for learning and memory. For all brain regions, ***p < 0.001; n ≥ 




Although NA reduction was severe in all regions surveyed, the cerebellum of Ear2 (-/-) mice lost a 
lower proportion of NA. That is, NA in the cerebellum was reduced by 31.8% compared to wild-
type mice. However, the olfactory bulb, frontal cortex and hippocampus of Ear2 (-/-) mice lost 
roughly twice as much NA. They each showed a 65.1%, 52.8% and 70% reduction in their NA 
levels, respectively.  
 
These data strongly suggest that a reduction of LC cells results in lower NA levels throughout the 
brain. LC reduction, however, did not seem to affect all brain regions equally. And the degree of 
NA loss varied greatly among brain regions. While LC cell number was reduced 43.55%, NA loss 
ranged from 30% in the cerebellum to 70% in the hippocampus. Indeed, the cerebellum is less 
innervated by the LC. Thus, LC reduction impacts the cerebellum to a lesser extent. On the other 
hand, LC highly innervates the olfactory bulb, cortex and hippocampus. And, they are highly 
affected by LC reduction. Importantly, these areas are relevant for learning and memory, which 
are the first to be affected in AD. This is also in agreement with the original observations in Ear2  
(-/-) mice [59]. Agenesis was reported to be preferential to the dorsal division of the LC which 
projects to cortical areas [59].  
 
 
2.1.5. Analysis of learning and memory 
In order to determine whether the chronic reduction of NA in brain regions relevant for memory 
had a functional impact, we submitted Ear2 (-/-) mice to a learning paradigm at 4 months of age. 
To investigate if and how the NA reduction affected cognitive function under an AD-like 
phenotype, Ear2 (-/-)/APP/PS1 mice were also analyzed. 
 
These experiments were carried out in collaboration with the group of Prof. Dr. Michael Heneka 
(Neurology Dept., University Clinic, Bonn). 
 
The Morris water maze (MWM) is a test of spatial learning and memory, where mice learn to find 
a hidden platform using spatial cues as a reference. Results from this test revealed that lower NA 
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levels or the presence of APP/PS1 transgenes caused a cognitive impairment (Fig. 8). This 
impairment was exacerbated when both factors were combined. Ear2 (-/-) mice had increased 
escape latencies and swam longer distances to reach the platform than wild-type mice (Fig. 8). A 
similar impairment was observed in mice carrying APP/PS1. Memory dysfunction was aggravated 
in Ear2 (-/-)/APP/PS1 mice and these mice took the longest time and swam the longest distances 





Fig. 8. Morris water maze assessment of spatial learning and memory. Cognitive functions were 
affected by NA reduction and APP/PS1 transgenes, while these characteristics combined were most 
detrimental to cognitive performance.  Latency and distance to escape to a hidden platform on 8 
consecutive days. Bar graphs represent the mean time (s) and distance (m) of each genotype over the 
complete duration of the experiment. Ear2 (-/-) and APP/PS1 mice showed a mild cognitive impairment 
compared to wild-type mice. Memory dysfunction was most profound, however, when both Ear2 (-/-) and 
APP/PS1 were present.  *p ≤ 0.05 (compared to APP/PS1-negative); #p ≤ 0.05 (compared to wild type); ’’p ≤ 
0.01 (compared to wild type); ’’’p ≤ 0.001 (compared to wild type);      n ≥ 10 animals per genotype. Error 




Importantly, we observed that the lack of the neurotransmitter caused a cognitive deficit. The 
chronic overexpression of the APP/PS1 transgenes also caused a similar impairment, even at this 
pre-plaque stage. Impaired spatial learning has been reported at 7 months of age [102]. Our data 
added to this reports showing that a deficiency is already detectable at 4 months of age. If a 
chronic lack of NA exists in an AD-like background, such as it is the case in Ear2 (-/-)/APP/PS1 
mice, cognitive functions seemed most affected. These data indicate that the effects of these 
factors are synergistic. The scenario in our model, of a chronic NA deficiency and an unbalanced 
Abeta production vs. clearance, resembles more closely the conditions of a future AD brain. 
Furthermore, our model is far more specific than previous models addressing LC ablation, typically 
targeting LC cells surgically or by treatment with the neurotoxin DSP-4. 
 
2.1.6. Confirmation of learning and memory deficiency  
To study in greater detail the learning and memory deficits observed in the Morris water maze, 
we performed electrophysiological recordings on hippocampal slices of 4-month-old mice. Since 
hippocampal synaptic plasticity is crucial for spatial memory formation, we recorded long term 
potentiation (LTP) of CA1 neurons. 
 
These experiments were carried out in collaboration with the group of Prof. Dr. Michael Heneka 
(Neurology Dept., University Clinic, Bonn). 
 
Schaffer collaterals were stimulated and field excitatory post synaptic potentials (fEPSP) were 
recorded in the pyramidal cell layer. After collecting a stable baseline response for at least 20 min, 
LTP was induced by theta burst stimulation (4 trains of 10 pulses at 100 Hz, 20 ms apart) (Fig. 9A). 
Peak slopes of fEPSP recordings were averaged over 5 min. before (baseline) and after LTP 
induction (Fig. 9A, B). We assessed early and late stages of LTP through responses at 10 min (T1) 
and 60 min (T2) after induction (Fig. 9C). Responses were normalized to baseline. Ear2 (-/-) and 
Ear2 (+/+)/APP/PS1 mice showed a modest but significant reduction at both early and late stages 
of LTP (T1 and T2) when compared to wild-type mice. However, slices from Ear2 (-/-)/APP/PS1 




              
Fig. 9. Electrophysiological recordings in sagittal brain slices of 4-month-old mice. Long term 
potentiation in hippocampal CA1 was impaired in Ear2 (-/-) and in Ear2 (+/+)/APP/PS1 mice. 
Impairment was most aggravated in Ear2 (-/-)/APP/PS1 mice and their ability to form LTP was nearly 
absent.  A) Representative responses to long term potentiation recorded in the pyramidal cell layer of the 
CA1 region. Induced potentials in Ear2 (-/-) and Ear2 (+/+)/APP/PS1 after tetanic stimulation seemed smaller 
than in wild-type mice. Ear2 (-/-)/APP/PS1 seemed almost unresponsive to tetanic stimulation.  B) 
Extracellular field excitatory postsynaptic potential (fEPSP) slope as percentage of baseline obtained before 
and after LTP induction. Early and late stages of LTP were analyzed 10 (T1) and 60 min (T2) after induction. 
Ear2 (-/-) and Ear2 (+/+)/APP/PS1 were indeed impaired in both phases of LTP (T1 and T2). Ear2 (-/-)/APP 
/PS1 had the greatest impairment at both time points. Late stage LTP (T2) was especially affected and fEPSP 
slope was very similar to baseline.  C) Quantification of early and late stages of LTP. A very similar early 
LTP (T1) impairment was observed for Ear2 (-/-) and Ear2 (+/+)/APP/PS1 mice. Impairment was moderate 
but significant. Early LTP impairment was most aggravated in Ear2 (-/-)/APP/PS1. Early LTP impairment in 
Ear2 (-/-) and Ear2 (+/+)/APP/PS1 became more pronounced in T2. Late LTP impairment was most 
aggravated in Ear2 (-/-)/APP/PS1; they were almost unable to form LTP. Factors were additive without 
interaction shown by two-way ANOVA. Student’s t-test: wild type vs. Ear2 (+/+)/APP/PS1 *p ≤ 0.05 for T1, 
***p ≤ 0.001 for T2; wild type vs. Ear2 (-/-) #p ≤ 0.05 for T1 and T2; Ear2 (-/-) vs. Ear2 (-/-)/APP/PS1 **p ≤ 
0.01 for T1 and T2; Ear2 (+/+)/APP/PS1 vs. Ear2 (-/-)/APP/PS1 #p ≤ 0.05 for T1 and T2; Ear2 (+/+) vs. Ear2 
(-/-)/APP/PS1 ’’’p ≤ 0.001 for T1 and T2; n ≥ 5 animals per group. Error bars indicate s.e.m. 
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To assure that LTP impairment could not be attributed to alterations in transmitter release from 
presynaptic terminals, we assessed paired pulse facilitation (PPF).  
 
Paired pulse facilitation refers to the higher (facilitated) post synaptic response to the second 
pulse, when 2 pulses (paired) are evoked presynaptically within a very short time (milliseconds 
apart). Facilitation occurs exclusively at the presynaptic terminal, from where neurotransmitter is 
released. Facilitation is thought of as the result of an increased probability of vesicular release of 
neurotransmitter. Thus, changes in PPF would report a change in transmitter release from pre-
synaptic terminals. PPF represents short-term presynaptic plasticity. 
 
Comparison of PPF recorded in CA1 with various interstimulus intervals revealed no changes for 
any of the genotypes (Fig. 10). Transmitter release seemed to be unaffected and thus not the 
cause of LTP impairment. 
 
 
         
Fig. 10. Paired pulse facilitation before and after 
LTP induction. Short term synaptic plasticity 
was unaffected by NA reduction. Paired pulse 
ratio was similar in all genotypes for all 
interstimulus intervals recorded (30, 50, 75 and 
100ms). Furthermore, PPF was not altered by LTP 
induction; ratio of PPF was the same before and 
after tetanic stimulation. n ≥ 5 animals per group. 





LTP deficits were not associated to deficits in short-term plasticity as indicated by an unaltered 
PPF ratio. These data indicate that neither the chronic reduction of NA, nor the overexpression of 
APP/PS1, nor the combination of these two factors has an effect on short-term synaptic plasticity.  
 
Furthermore, the ratio of PPF was unchanged before or after LTP induction (Fig. 10). These data 




2.1.7. Rescue of memory impairment 
To prove that cognitive deficits seen in our new mouse model were NA specific, we supplied the 
NA-deficient brains with the NA precursor L-threo-DOPS. 
 
These experiments were carried out in collaboration with the group of Prof. Dr. Michael Heneka 
(Neurology Dept., University Clinic, Bonn). 
 
L-threo-3,4-dihydroxyphenylserine (DOPS) was i.p. injected together with benserazide, an 
inhibitor of aromatic acid decarbosylase (AADC) in the periphery, to restore NA levels exclusively 
in the brain. AADC is needed for the conversion of DOPS to NA. Benserazide inhibits AADC and is 
unable to cross the brain-blood-barrier. Thus, co-injection of DOPS and benserazide restores NA in 
the brain exclusively and not in the periphery [74]. NA made in the adrenal gland supplies the 
periphery and i.p. injection of a NA would interfere with our test by increasing the heart rate and 
causing hyperactivity. Mice were treated daily with DOPS and analyzed in the MWM 5 hours later, 
when cerebral NA levels were shown to peak in Dbh (-/-) mice [74].  
 
DOPS treatment partially rescued spatial learning and memory deficits in Ear2 (-/-)/APP/PS1 mice. 
DOPS-injected Ear2 (-/-)/APP/PS1 mice found the hidden platform significantly faster than vehicle-
treated controls (Fig. 11). Two-way ANOVA with repeated measures revealed a significant effect 
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of DOPS for time (F(1,45) = 4.53, p ≤ 0.5) but not for distance. However, DOPS-treated Ear2 (-/-)/APP 
/PS1 mice swam significantly less distances from days 5 to 8 than vehicle-treated controls 
(Student’s t-test for days 5 to 8, p ≤ 0.05). 
 
                
                      
 
Fig. 11. Morris water maze assessment of spatial learning and memory after acute restoration of NA in 
the brain. Treatment with the NA precursor L-threo-DOPS restored cognitive deficits arising from a 
genetic NA depletion. Four-month-old mice received daily i.p. treatments of DOPS and benserazide, an 
inhibitor of aromatic acid decarboxylase (AADC). AADC converts DOPS to NA. Because benserazide is 
unable to cross the brain-blood-barrier, co-injection restores NA exclusively in the brain and not the 
periphery. DOPS-treated Ear2 (-/-)/APP/PS1 mice performed significantly better in the MWM compared to 
vehicle-treated mice (injected with vehicle solution). Performance of treated mice was comparable to that of 
Ear2 (+/+)/APP/PS1, suggesting that at least the contribution of a reduced LC to the cognitive impairment 
can be alleviated by acute NA supplementation. Student’s t-test over all days: Ear2 (-/-)/APP/PS1 vs. Ear2   
(-/-)/APP/PS1 + DOPS 
$




Acute NA restoration partially rescued the spatial memory impairment caused by a genetic NA 
deficiency even under an AD-like background. In the Ear2 (-/-)/APP/PS1 mice, DOPS treatment 
brought performance in the MWM to a comparable level to Ear2 (+/+)/APP/PS1 mice. These data 
suggest that, at least in part, cognitive deficits seen in our model are caused by the lack of NA 
specifically. Furthermore, these data suggest that at least the NA deficiency component of 
cognitive impairment in an early AD-like environment can be rescued by acute NA reinstatement. 
 
 
2.1.8. Analysis of LC size in aged mice 
In order to analyze long-term effects of NA deficiency, we analyzed the LC nucleus in 1-year-old 
mice. 
 
In situ hybridization (ISH) with Th marks LC cells (Fig. 12A). As expected, considerably less Th 
signal could be observed in aged Ear2 (-/-) mice. The presence of APP/PS1 did not seem to affect 
LC size and Th signal was similar in sections of APP/PS1 positive and negative mice. Quantification 
of Th(+) cells revealed a moderate 9.16% reduction of Th(+) cells in aged Ear2 (+/+)/APP/PS1 mice 
(Fig. 12B). Aged wild type mice had an average of 1284.8 (±127.8) Th(+) cells per LC, while aged 
Ear2 (+/+)/APP/PS1 mice had 1167.1 (±69.6) cells per LC. Th(+) cell number was markedly less in 
Ear 2 (-/-) mice, regardless of APP/PS1. Aged Ear2 (-/-) and aged Ear2 (-/-)/APP/PS1 mice had 
542.1 (±97) and 553.9 (±86.9) Th(+) cells per LC, respectively.  
 
Comparison of the number of Th(+) cells in 3-month and 1-year-old mice showed that the NA 
producing nucleus remained for the most part intact through aging (Fig. 12C). Surprisingly, only 
wild-type mice seemed to have fewer Th(+) cells. The number of LC cells remained constant 







Fig. 12. LC size in 1-year-old mice and comparison to 3-month-old mice. LC cells of aged APP/PS1 
mice seemed to be slightly less than in aged wild-type mice. The loss of Th(+) LC cells in Ear2 (-/-) 
with or without APP/PS1 was extremely significant. Comparison of LC cell number in young and 
aged revealed that for the most part the nucleus remained intact. Th marks LC cells.  A) In situ 
hybridization of coronal sections of 1-year-old mice. Ear2 (-/-) mice with or without APP/PS1 showed 
markedly reduced Th staining compared to wild-type controls.  B) Quantification of Th(+) cells showed 
a 57.8% reduction of LC cells in aged Ear2 (-/-). Aged Ear2 (+/+)/APP/PS1 had a modest, yet 
significant, reduction of Th(+) cells compared to aged wild-types.  C) Comparison of Th(+) LC cells in 
3-months and 1-year-old mice. Interestingly, the only difference was seen in wild-type mice. Otherwise, 
the nucleus remained intact and Th(+) cell numbers were very similar in young and aged mice of the 
same genotype. *p< 0.05; **p < 0.01; ***p < 0.001; n=10 each genotype. Error bars indicate s.e.m. 
 
 
The decrement of Th(+) neurons in aged Ear2 (-/-) mice represented a 57.8% LC loss. At 1 year of 
age, APP/PS1 mice continued to have slightly less LC neurons than wild-type mice. Besides, no 




These data indicate that the LC remains intact even after a long-term lack of NA or long-term 
plaque deposition. Through the aging process, the nucleus seems moderately affected. Whether 
this is functionally relevant will be addressed in the following experiments.  
 
 
2.1.9. Effects of aging on NA levels 
To analyze whether aging affected NA levels under normal and diseased conditions we quantified 
NA concentrations in the olfactory bulb, frontal cortex, hippocampus and cerebellum and 
compared them to those at 3 months of age. 
 
2.1.9.a. HPLC quantification of NA in the brain of aged mice 
HPLC was used to quantify NA content in learning-relevant regions, with high LC innervations (Fig. 
13). We concentrated on the same brain regions as in the young 3-month-old cohort. They are 
olfactory bulb, frontal cortex, hippocampus and the cerebellum, the later taken as control tissue. 
NA concentration in the olfactory bulb of aged wild-types was 0.3842 (±0.046) ng/mg of tissue, 
while Ear2 (-/-) only had 0.0907 (±0.011) ng/mg of tissue (Fig. 13A). The frontal cortex of wild type 
mice contained 0.4672 (±0.013) ng/mg of tissue. And NA dropped to 0.1872 (±0.012) ng/mg of 
tissue in the Ear2 (-/-) (Fig. 13B). Similarly, NA concentration in the aged hippocampus was 0.4573 
(±0.055) ng/mg of tissue and only 0.1144 (±0.012) ng/mg of tissue in wild-type and Ear2 (-/-), 
respectively (Fig. 13C). NA content in the cerebellum of aged wild-type mice was 0.5029 (±0.074) 
ng/mg of tissue and in Ear2 (-/-) 0.2485 (±0.034) ng/mg of tissue (Fig. 13D). 
 
NA content in aged mice carrying APP/PS1 was only significantly lower in the olfactory bulb and 
frontal cortex as compared to wild-type mice (Fig. 13A, B). NA concentration in the olfactory bulb 
was 0.2796 (±0.055) ng/mg of tissue in aged APP/PS1 mice, while in the frontal cortex was 0.3534 







Fig. 13. HPLC quantification of noradrenaline concentration in the brain of 1-year-old mice. Areas 
relevant to learning and memory and with high LC innervations had the greatest NA loss.  A) NA loss 
in the olfactory bulb of 1-year-old Ear2 (-/-) and Ear2 (-/-)/APP/PS1 mice. Ear2 (-/-) mice showed a 76.4% 
loss of NA, while APP/PS1 lost 27.2%.  B) In the frontal cortex, 1-year-old Ear2 (-/-) mice lost 59.9% NA 
and APP/PS1 mice loss 24.4% NA compared to wild-type mice.  C) NA levels in the hippocampus of aged 
Ear2 (-/-) mice had a reduction of 75%. APP/PS1 had no significant impact on NA levels.  D) NA reduction 
in the cerebellum of 1-year-old Ear2 (-/-) was 50.6% compared to wild-types. For all brain regions, *p< 0.05; 
**p < 0.01; ***p < 0.001; n ≥ 5 each genotype. Error bars indicate s.e.m. 
 
 
Compared to wild-type, aged Ear2 (-/-) mice lost 76, 60 and 75% NA in olfactory bulb, cortex and 
hippocampus, respectively. These losses were higher than in young mice. For example, in the 
olfactory bulb, young Ear2 (-/-) mice lost 65% and aged 76%. In the frontal cortex, NA deficiency 
went from 53 to 60%, while in the hippocampus from 70 to 75%. The 32% NA loss in the 
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cerebellum of 3-month-old Ear2 (-/-) reached 51% by 1 year of age. These data indicate that a 
chronic NA deficiency seems to be accentuated with aging. 
 
2.1.9.b. Comparison of NA content in young vs. aged mice cohorts 
Next, we compared NA concentration in young and aged mice to see whether aging affected NA 
levels throughout the brain under a wild type and disease environments.  
 
In wild-type mice, NA levels remained constant through aging in all brain regions probed (Fig. 
14A). From 3 months to 1 year of age, APP/PS1 mice lost 21.2% NA in the olfactory bulb, 31.7% in 
the frontal cortex, 26.9% in the hippocampus and 35.4% NA in the cerebellum (Fig. 14B). NA loss 
over time for Ear2 (-/-) mice was also around 25% (Fig. 14C). Aged Ear2-deficient mice lost 27.5, 
14.5, 28.5 and 21.9% NA in the olfactory bulb, frontal cortex, hippocampus and cerebellum, 
respectively. Although NA loss was only significant in the cerebellum, NA values for the other 
regions were probably too small to reach significance. Ear2 (-/-)/APP/PS1 mice had the greatest 
NA loss (approx. 45%) for all brain regions surveyed, except for the cerebellum (Fig. 14D). NA loss 
in the olfactory bulb was 48.9%, in the frontal cortex 43.2% and in the hippocampus 42.3%. 







Fig. 14. Comparison of NA levels through aging. Chronic NA deficiency was most accentuated over 
time under an AD-like background.  A) NA concentration in 3-month and 1-year-old wild-type mice. NA 
levels remained constant throughout aging in all brain regions.  B) NA content in brain regions of 3-month 
and 1-year old Ear2 (+/+)/APP/PS1 mice. Bars of wild-type values (as in A) were included as reference. By 1 
year of age, mice carrying APP/PS1 had lost approx. 25% NA.  C) Aged Ear2 (-/-) also lost 25% NA approx. 
from 3 to 12 months of age, although no significance was reached. Bars of wild-type values (as in A) were 
included as reference.  D) NA content in aged Ear2 (-/-)/APP/PS1, however, dropped to about half from 3 
months to 1 year. Bars of wild-type values (as in A) were included as reference. For C and D: Levels of NA 
in young and aged Ear2 (-/-) with or without APP/PS1 are still extremely significantly lower than in wild 
types (as shown in figures 3 and 9). OB, olfactory bulb; FC, frontal cortex; HC, hippocampus; CB, 
cerebellum; *p< 0.05; **p < 0.01; ***p < 0.001. Error bars indicate s.e.m. 
 
 
These data indicate that a) under normal conditions (wild-type) there is no NA loss as an effect of 
aging in our mice, at least not up to 1 year of age, and that the apparent LC size reduction seen by 
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ISH is seemingly not reflected in NA levels; b) long-term over expression of APP/PS1 or long-term 
chronic NA deficiency seemed to deregulate the noradrenergic system to decrease NA in the 
brain; and c) long-term chronic NA deficiency under a diseased environment, such as in Ear2 (-/-)/ 
APP/PS1, is most detrimental to the noradrenergic deregulation. This scenario resembles closer 
that of MCI or early AD because LC degeneration occurs before patients become symptomatic. 
Considering that the lack of NA created cognitive deficits already at 3 months, it is not difficult to 
imagine that the impairment in aged Ear2 (-/-)/APP/PS1 would also be incremented over time, 





2.2.1. Mouse models of AD and LC loss 
Many models of AD exist to date; however, most do not mimic LC loss and we rely on chemical or 
surgical ablation of LC neurons to study this feature of the disease. Chemical or surgical ablation 
of LC neurons is invasive and it may cause other effects by off-target disruption of cells or by 
activating compensatory responses after lesion [75,76,77]. 
 
Neuronal loss has been detected in a few transgenic AD models, but this is almost exclusively in 
the hippocampus and at older ages [61,68,103,104]. Importantly, LC cell death is nonexistent at 
pre-plaque stages in transgenic mice [60]. LC cell loss has previously been reported in the APP/PS1 
model used in this study only well after plaque deposition has begun [70]. This is not the clinical 
scenario. Degeneration of LC neurons occurs very early in AD, presumably even before AD-like 
symptoms manifest [29,33].  The Ear2 (-/-)/APP/PS1 model has a reduced LC, concomitant 
reduced NA levels throughout the brain and an enhanced cognitive impairment compared to 
APP/PS1 mice. Albeit with a NA reduction from embryonic stages, the Ear2 (-/-) mice develop 
properly and no other overt developmental deficiency was detected [59]. The chronic lack of 
proper NA levels well before the onset of plaque deposition combined with a well-established AD-
like background yields a better approximation to the clinical scenario seen in human patients. We 
therefore propose the Ear2 (-/-)/APP/PS1 to be a better mouse model for the study of early LC 
loss and the contribution of chronic NA deficiency to the progression of AD. 
 
 
2.2.2. Functional consequences of Ear2 knock out and AD 
While the developmental anatomical consequences of lacking Ear2 are having a locally reduced 
LC, the functional consequences extend throughout the brain. First, lower NA levels are found 
throughout the brain, especially in those regions with high LC innervations. These regions are also 
important in memory. This is in agreement with published literature reporting lower NA levels in 
LC projecting regions upon  LC neuronal loss [4,31,32,35]. Second, learning and memory are 
impaired. Our data show that chronic lack of NA in the brain causes learning and memory deficits. 
These deficits seem greater in the memory consolidation phase, days 4 to 8 of the Morris water 
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maze (MWM) than in the acquisition phase (days 1 to 4) (Fig. 8). Published data have also 
implicated NA in memory consolidation [49,105]. More importantly, these results are validated by 
another NA-deficient mouse model, the Dbh (-/-) [106], where consolidation rather than 
acquisition was affected. NA deficiency in the Ear2 mutant mice has a genetic basis and they do 
not undergo invasive procedures nor do they receive toxic treatments before studies are 
performed. Our data can better establish that it was indeed the lack of NA what caused the 
cognitive impairments observed. 
 
Alone, APP/PS1 seemed to have a detrimental effect on learning and memory in an NA-
independent fashion. The cognitive impairment seen in these mice in the MWM and LTP 
recordings could not be associated to NA because NA levels in these mice were comparable to 
those of wild-type mice and re-supplying the brain with NA in Ear2 (-/-)/APP/PS1 rescued only the 
contribution of Ear2 (-/-) to cognitive impairment. Yet, when APP/PS1 were combined with NA 
deficiency, cognitive impairments were exacerbated. The combination of chronically lacking 
proper NA levels with an AD-like diseased environment seems most detrimental to cognitive 
performance compared to having each one of these characteristics alone. Results from the MWM 
test and from LTP recordings showed Ear2 (-/-)/APP/ PS1 mice as having the worst cognitive 
impairment (Fig. 8; 9) as compared to all control groups, namely wild-type, Ear2 (-/-) or APP/PS1 
mice. These data suggest that NA is associated to the intensity of an AD-like phenotype at a pre-
plaque stage. A scenario that is also likely to occur in MCI patients. These results are consistent 
with published studies reporting a DSP-4-induced impairment in working and reference memory 
in APP23 transgenic mice [38]. Previous reports have also shown APP/PS1 mice to be impaired in 
learning, memory, synaptic transmission and LTP [102,107]. 
 
 
2.2.3. Chronic NA deficiency does not facilitate plaque deposition 
Owing to their reduced NA levels, Ear2 (-/-) mice also miss the proper NA anti-inflammatory signal 
in the brain [52]. Plaque loci are also sites of higher inflammation [38,67]. CD11b(+) activated 
microglia surround plaques in a mechanism that is thought to aid plaque clearance [55]. 
Furthermore, reduction in LC neurons has been associated with Abeta deposition [38], 
neurofibrillary tangles [13] and the severity and onset of dementia [34,35]. It would be then likely 
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that a genetic NA deficiency could facilitate plaque deposition and that Ear2 (-/-)/APP/PS1 mice 
would have an elevated plaque load. At 6 months of age, this was however not the case. 
Thioflavin S staining of 6-month-old Ear2 (-/-)/APP/ PS1 brains showed identical plaque deposition 
when compared to APP/PS1 age-matched controls (Fig. 6). We cannot rule out the possibility that 
NA deficiency indeed contributes to plaque burden at a later stage. Plaques deposition may also 
not be directly affected in our system as it is also not the only feature of AD and other molecular 
features would need to be assessed. 
 
 
2.2.4. Memory deficits in Ear2 (-/-) are controlled by LC NA 
Ear2-deficient mice have a cognitive impairment due to lack of NA from LC neurons and 
treatment with the NA-agonist, L-Threo DOPS, alleviates the spatial memory and learning deficits 
seen in the MWM. Although lower NA in the mutant Ear2 mice originates from developmental 
stages, rescue of cognitive performance by DOPS treatment shows that NA and no other 
developmental defect affects the cognitive performance of Ear2 (-/-) mice. This finding becomes 
more relevant if we consider that apart from NA, LC neurons also produce other 
neuromodulators. Among others, NPY[57], galanin [57], cocaine- and amphetamine-regulated 
transcript (CART)[58] and BDNF [56] are produced by the LC. 
 
Consistent with our findings in Ear2 (-/-), L-Threo DOPS is able to partially alleviate the cognitive 
deficits in Ear2 (-/-)/APP/PS1 (Fig. 11). DOPS alleviates the spatial learning and memory 
impairment in as much as Ear2 (-/-) (or chronic NA deficiency) contributes to the impairment. 
DOPS ability to only partially rescue cognitive functions suggests that NA deficiency intensifies the 
AD-like phenotype at stages before the onset of plaque deposits. Although the mechanisms of 
action of NA deficiency and APP/PS1 overproduction might act independently of each other to 
produce an AD-like phenotype, NA deficiency certainly aggravated cognitive performance and 
thereby acted as a modifier for the disease. This is relevant to the treatment of AD pathology 
because our findings suggest that successful treatment might require a combination of drugs. Our 
findings speak for NA as a potential therapeutic to partially alleviate an initial cognitive deficit. 




2.2.5. NA levels in aged mice 
At 1 year of age, regions most innervated by the LC had the greatest NA loss. These findings were 
not unexpected as this was also the case for 3-month-old mice. Interestingly, however, by 1 year 
of age APP/PS1 mice showed significantly lower NA levels than their age-matched wild-type 
controls (Fig. 13), reflecting a greater systemic deregulation after 6 months of plaque 
accumulation. Lower NA levels, comparable to the ones we report here, have also been reported 
in older transgenic mouse models of AD [39,67,108]. One-year-old Ear2 (-/-)/APP/PS1 tended to 
have even lower NA concentration in memory-relevant regions than Ear2 (-/-) (Fig. 13B, C). These 




2.2.6. NA levels through aging in wild-type and diseased conditions 
In order to reveal whether NA levels had an aging component, we compared NA content in 3-
month and 1-year-old mice. NA content in wild-type mice remained constant through aging. This 
is contrary to what is reported for humans, where NA decreases with age [44]. We cannot rule out 
the possibility that NA in wild-type mice could decrease at an older age. Surprisingly, the number 
of LC cells decreased by 10% from 3 months to 1 year in wild-type mice (Fig. 12C). Because the 
decrease is not dramatic, there seems not to be an aging component to NA levels in 1-year-old 
wild-type mice. 
 
The already low NA levels in young Ear2 (-/-) mice dropped to even lower levels with age and we 
observed and approx. 25% NA decrease in all regions analyzed (Fig. 13C). NA loss was not 
associated to LC cell loss because the number of Th(+) cells at 3 months and 1 year were the 
same. Chronic NA deficiency seems to be accentuated with age, suggesting there may be a 
negative feedback signaling. Surprisingly, Ear2 deficiency deregulates the expression of only a very 
small set of genes in the hippocampus (microarray data shows 18 up and 5 down regulated genes; 
unpublished data from Prof. Henneka’s lab), indicating only a more local impact. Whether the NA 
decrease in aged mice is the result of a compensatory regulation of NA over a long-term impaired 
brain that was already less plastic, or an overall poor signaling circuitry back to the LC, would have 
to be further investigated.  
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Ear2 (+/+)/APP/PS1 mice had modestly less LC cells than wild-type mice at 3 months and 1 year of 
age (Fig. 5B; 12B, C). This is in keeping with published literature reporting a high LC loss in the 
same APP/PS1 transgenic model at an older age (16 to 23 months) [70]. Taken together, APP/PS1 
seemed to have a gradual but steady loss of LC neurons, perhaps facilitated by plaque 
accumulation. NA levels were similar to wild-type mice at 3 months and lower at 1 year. And 
through aging, APP/PS1 lost approx. 25% NA. Lower NA levels at post-plaque stages has also been 
reported for other APP transgenics, such as in the PS:APP [39,108] and 5xFAD TgAPP [67] mice. 
These data argue for the transgenes to exert a deregulatory effect on the NAergic system perhaps 
by their long-term overexpression and the accumulated aggregation of Abeta plaques. 
Accordingly, microarray data (unpublished data from Prof. Henneka’s lab) from hippocampus of 
Ear2 (+/+)/APP/PS1 mice revealed the expression of over 800 genes to be deregulated. 
 
Ear2 (-/-)/APP/PS1 mice lost over time almost twice as much NA as Ear2 (-/-) or APP/PS1 alone, 
indicating these two factors to act towards aggravating the AD-like symptom, even if through 
independent mechanisms.  
 
In conclusion, our model recapitulates AD in a more faithful manner. Namely, we observed in our 
model the LC loss, decreased levels of NA, higher cognitive impairments and an AD-like pathology 
that was reinforced with age. Thus, we propose our model to be a more suitable one to study 
early stages of AD and potential therapeutic compounds. Furthermore, we propose NA to be a 











3.1.1. Construct design 
Our objective was two-fold. First, we aimed to fill the need for a more fine-tuned and faithful 
model of Parkinson’s disease. Second, we wanted to test in-vivo the neurotoxicity of a fibril-
deficient Synuclein carrying three Ala->Pro substitutions at positions 30, 56 and 76 (triple-proline, 
TP-Snca). 
 
Biophysical data have previously shown TP-Snca to produce a Synuclein variant that is less able to 
form fibrils but have higher amounts of soluble oligomers [100]. In addition, TP-Snca was shown 
to have impaired aggregation properties but to be more toxic in mammalian neuronal cultures or 
in lower organisms [100]. 
 
The design of our targeting construct was carried out by Dr. Xunlei Zhou. The objective was to 
create a conditional synuclein knock out/knock in model. Endogenous expression was sought 
after and we cloned into the endogenous mouse Snca locus. Additionally, spatio-temporal 
regulation of TP-SNCA gene expression was achieved by generating a conditional mutant. 
Expression of TP-SNCA will be exclusively directed to cells of the dopaminergic system utilizing the 
Cre/loxP system.  
 
The targeting vector contained a wild-type human SNCA that was preceded by a genomic intronic 
sequence containing the endogenous splicing acceptor and flanked by two loxP sites (Fig. 15). 
Next, a splicing acceptor was included to lead the splicing machinery into the TP-Snca cassette 
immediately following downstream. An alkaline phosphatase cassette was also included as 
reporter. Finally, we included a neo cassette flanked by FRT sites as a selection marker for 






Fig. 15. Schematic representation of construct design.  Human wild-type α-synuclein (SNCA) was 
preceded by a short murine genomic intron sequence (containing the endogenous splicing acceptor) and 
flanked by two loxP sites. A splicing acceptor (SA) preceded the triple-proline-substituted SNCA (TP-
SNCA) and an alkaline phosphatase reporter (pLAP) cassette. An FRT-flanked neomycin (Neo) cassette was 
included as a selection marker for homologous recombination. Human wild-type SNCA will be produced in 
these mice. Upon crossing to a DAergic-specific cre-driver line, e.g. the dopamine transporter-cre mouse 
line, dopaminergic neurons of the Substantia Nigra and ventral tegmental area exclusively will switch to 
produce the TP-SNCA. pA, poly A tail; IRES, internal ribosome entry sites; FRT, flippase recognition 
target; PGK, phosphoglycerate kinase promoter. 
 
 
3.1.2. Cloning strategy 
To be able to work in parallel, our cloning strategy was such that we cloned into a cloning vector 
from both the 5’ and 3’ ends of the construct. The cloning strategy was set to pre-assemble 4 
different expression cassettes and to subsequently clone them into the cloning vector using 
restriction enzymes. ET-cloning was also used, first to bring genomic DNA sequence of the Snca 
locus into the targeting vector, then to clone an additional tetracycline selection cassette and 
finally to bring our final construct from the cloning into the targeting vector.  
 
This work was carried out in collaboration with Dr. Insa Geffers. All plasmids were kindly provided 




3.1.2.a. Preparation of the pXL112-DTA-genomic SNCA-Tet vector for cloning of the final 
construct 
3.1.2.a.i. ET cloning of genomic Snca DNA into pXL112-DTA 
First, the genomic targeted region of Snca was brought into the pXL112-DTA vector from a 
commercially available BAC clone. We included 5’ (5582 bp) and 3’ (3298 bp) homologous arms 
from the targeted region (Fig. 16). 
 
The pXL112-DTA vector contained the Diphtheria toxin A (DTA) cassette for negative selection of 
ES cells in which homologous recombination did not occur.  
 
In order to be able to use ET cloning, we first cloned two short homologous sequences of approx. 
500 bp each into pXL112-DTA using restriction enzymes. We called these H1 and H2.  
 
H1 laid at the 5’ end of the 5’ homologous arm (Fig. 16). The H1 fragment was first amplified from 
the BAC clone by PCR reaction. We included restriction sites for BglII or EcoRI at the 5’ end of each 
the forward and reverse primers, respectively. The 520 bp H1 amplicon was then cloned into the 
pXL112-DTA vector using these restriction enzymes.  
 
Analogously, H2 laid at the 3’ end of the 3’ homologous arm (Fig. 16). H2 was also PCR amplified 
from the BAC clone. We included restriction sites for EcoRI or XhoI at the 5’ end of each the 
forward and reverse primers, respectively. The 517 bp H2 amplicon was then cloned into the 
pXL112-DTA vector using these restriction enzymes to obtain the pXL112-DTA-H1-H2 vector. 
 
We then used the homologous H1 and H2 sequences to perform ET cloning. We cloned a 9 kb 
genomic region from the Snca gene locus into the pXL112-DTA-H1-H2 vector (Fig. 16). This vector 







Fig. 16. Preparation of the pXL-112-DTA-genomic SNCA-Tet vector. The pXL112-DTA vector contained 
the Diphtheria toxin A (DTA) negative selection cassette for homologous recombination in ES cells. ET 
cloning was used to bring genomic Snca sequence from a BAC clone into the pXL112-DTA vector using the 
short homologous sequences H1 and H2. These ca. 500 bp fragments were first PCR-amplified from the 
BAC clone using primers containing restriction sites at their 5’ends. They were then cloned into the pXL112-
DTA vector using restriction enzymes. 5’ and 3’ homologous arms were approx. 5 and 3.5 kb long, 
respectively. H3 and H4 homologous fragments were used for ET cloning of the final construct into the 
pXL112-DTA-genomic SNCA-Tet vector. H3 and H4 were amplified and cloned in a similar fashion as H1 
and H2. Ex1, exon 1; Ex2, exon 2. 
 
 
3.1.2.a.ii. Preparation of an additional selection cassette, the tetracycline cassette 
Analogous to H1 and H2, 2 short homologous sequences flanking the targeted region 
(endogenous splicing acceptor and 48 bp into exon 3 containing the start codon) were also 
designed. These H3 and H4 fragments of 490 bp and 399 bp, respectively, were PCR-amplified 
from the BAC clone. H3 forward primer included a SfiI restriction site and H3 reverse primer a SbfI 
at their 5’ ends. H4 forward and reverse primers included a XmaI and a SalI restriction sites, 
respectively. These PCR products were then sequentially cloned into the pXL117 vector.  
 
In addition, a tetracycline selection cassette (1647 bp) was cloned between H3 and H4 using the 
restriction enzymes XhoI and BamHI. The tet cassette had been previously PCR-amplified with 





3.1.2.a.iii. ET cloning of the tetracycline cassette into the pXL112-DTA-genomic SNCA vector 
Using ET cloning with the short homologous sequences H3 and H4 we brought the tet cassette 
from pXL117-H3-tet-H4 into pXL112-DTA-genomic SNCA. The tet cassette replaced 250 bp of the 
targeted sequence in the pXL112-DTA-genomic SNCA vector (Fig. 16). The final sequence of DNA 
fragments in the vector was: pXL112- H1-5’ homologous arm- H3- tet - H4- 3’ homologous arm- 
H2. However, for practical purposes, this vector was termed pXL112-DTA-genomic SNCA-tet. 
 
The purpose of the tet cassette was not only to introduce an additional selection but also to avoid 
having the 228 bp-long genomic intronic sequence containing the endogenous splicing acceptor 
and beginning of exon 3, which would be available for homologous recombination (alternative to 
H3) because they were also included in the final construct. This would result in a missing loxP site 
5’ of SNCA. This was indeed the case in a previous trial and thus this step had to be implemented. 
This step prepared the vector for cloning of the final construct. Preparation of the final construct 
is describe in the following section. 
 
  
3.1.2.b. Preparation of cloning cassettes and assembly of the final construct 
The cloning strategy for the final construct involved the pre-assembly of 4 different cloning 
cassettes (Fig. 17) and their subsequent cloning into the pXL117-H3 or pXL117-H4 cloning vectors 
using restriction enzymes. Cassettes on the 5’ end of the construct (Fig. 17, cassettes A and B) 
were cloned into pXL117-H3. Cassettes on the 3’ end of the construct (Fig. 17, cassettes C and D) 
were cloned into pXL117-H4. Cloning from both ends of the construct was carried out in parallel 







Fig. 17. Preparation of expression cassettes. The cloning vector consisted of four pre-assembled cloning 
cassettes A - D. 
 
 
3.1.2.b.i. Assembly of the human SNCA cassette flanked by loxP sites 
In order to assure the most faithful endogenous expression of our construct, 202 bp of genomic 
intron sequence [containing the splicing acceptor (SA)] and 48 bp into exon 3, immediately 
upstream of the start codon, were included. This cassette had thus 4 components: the loxP sites, 
the intron/exon sequence (250 bp), the SNCA open reading frame (ORF) and a polyA tail. The 
SNCA ORF and the intron/exon sequence were PCR-amplified and brought together by a 3-step 
PCR protocol. First, the intron/exon sequence was amplified from the genomic region using a 
forward primer containing a 5’ - NheI restriction site and a reverse primer containing at its 5’ end 
9 bases of homology to the beginning of SNCA ORF. SNCA was similarly amplified from the pT7-7-
SNCA vector (kindly provided by Prof. Dr. Markus Zweckstetter, Max Planck Institute for 
Biophysical Chemistry, Gottingen). Attached to the 5’ end of the forward primer were 9 bases of 
homology to the end of the PCR product above (9 last bases of the 48 bp into exon 3). A BclI site 
was attached to the 5’ end of the reverse primer. The resulting PCR products (intron/exon 
sequence, 250 bp and SNCA ORF, 423 bp) were added as templates for a third round of PCR 
amplification with the forward primer of the intron/exon sequence and the reverse primer of 
SNCA. Since the two templates had overlapping sequences at the ends, they hybridized 
generating a PCR product of a fused intron/exon sequence-SNCA fragment (673 bp).  This PCR 
product was then cloned using NheI and BclI into the pL452 vector. This vector included a poly A 
tail and a loxP site 5’ of the BclI site. An additional loxP site was conveniently located 3’ of the 




The floxed-SNCA cassette (Fig. 17, cassette A) was released from pL452-SNCA using PstI and XhoI 
and cloned into the pXL117-H3 vector previously linearized with SbfI, which forms compatible 
ends to PstI, and XhoI. This formed the pXL117-H3-floxed-SNCA vector. 
 
 
3.1.2.b.ii. Assembly of the triple-proline substitution SNCA (TP-SNCA) cassette with a preceding 
splicing acceptor (SA) 
The strong splicing acceptor sequence from Engrail2 (En2-SA, 1789 bp) was excised out of pGT0 Z-
AP using SalI and XbaI restriction enzymes.  
 
TP-SNCA was PCR-amplified (447 bp) from the pT7-7-TP-SNCA vector (kindly provided by Prof. Dr. 
Markus Zweckstetter, Max Planck Institute for Biophysical Chemistry, Gottingen). The forward 
primer contained an XbaI site and it was followed by the Kozak sequence 5’-C GCC ACC -3’. The 
reverse primer contained a SacII site.  
 
The En2-SA and TP-SNCA cassettes were linked through the XbaI site and pre-assembled into the 
pGem®-T Easy system (Promega). This cassette (Fig. 17, cassette B) was then released using SalI 
and SacII and cloned into the pXL117-H3-SNCA vector, previously linearized with SalI-compatible 
XhoI and SacII. This step completed the pXL117-H3-floxed-SNCA-TP-SNCA vector (Fig. 17, cassettes 
A and B). 
 
 
3.1.2.b.iii. Assembly of the selection marker, neomycin cassette flanked by FRT sites 
We PCR-amplified the neo cassette and flanking FRT sites using the pL451 rc vector as template, a 
forward primer containing a KpnI site and a reverse primer covering the EcoRV site present in the 
plasmid were used. The 1848 bp PCR product (Fig. 17, cassette D) was cloned into pXL117-H4, 




3.1.2.b.iv. Assembly of the reporter cassette, placental-like alkaline phosphatase (pLAP) 
An internal ribosome entry site (IRES) preceded the pLAP and polyA fragment. This cassette (Fig. 
17, cassette C) was excised using EcoRI from the pGT0 Z-AP plasmid. The EcoRI 5’-overhangs were 
excised using the Mung Bean enzyme. The cassette was blunt-end cloned into pXL117-H4-FRT-
Neo previously linearized with the blunt cutter SwaI. Clones with the right orientation were 
identifed by restriction mapping. 
 
The final step in the preparation of the construct consisted of bringing both ends together. This 
was accomplished by a final step of directional cloning using AsiSI and SalI to excise cassettes C, D 
and H4 from pXL117-H4-IRES-pLAP-FRT-Neo. This insert was cloned into the pXL117-H3-floxed-
SNCA-TP-SNCA vector. The final construct in the cloning vector was: pXL117-H3-floxed-SNCA-TP-
SNCA-IRES-pLAP-FRT-Neo-H4 (Fig. 13, cassettes A to D). 
 
 
3.1.2.c. Assembly of the targeting vector 
A third and final round of ET cloning was performed using the homologous H3 and H4 sequences 
in order to bring the final construct from the pXL117 cloning vector (Fig. 17) into the pXL112-DTA-
genomic SNCA-tet vector (Fig. 16). This step replaced the tet cassette with the cloning cassettes. 






              
Fig. 18. Targeting vector and targeted allele of Snca.  
 
 
3.1.3. Electroporation of the targeted vector into ES cells and ES cell selection 
The final targeting vector was linearized with SalI. Electroporation of the purified DNA into ES cells 
and selection of ES cells that are resistant to G418 (neomycin analog) was kindly performed by 
Sharif Mahsur (Transgenic core facility, MPI for Biophysical Chemistry, Gottingen). 
 
 
3.1.4. Screening of ES cell clones 
PCR and Southern blot screening of ES cell clones was performed by Dr. Insa Geffers. Genomic 
DNA of 238 ES cell clones was pre-screened by PCR. One hundred and seven clones were positive 
by PCR screening. These were subsequently subjected to Southern blot analysis. So far, 2 correctly 
62 
Results: PD 
targeted ES cell clones have been identified out of 61 clones screened by Southern blot of BglII or 
BlpI-digested ES cell DNA using external probes located 5’ and 3’ of the homologous arms, 
respectively (Fig. 19). In the near future, verified ES cell clones will be used for blastocyst injection 
to generate chimeric mice.  
 
 
                  







3.2.1. Mouse models of PD 
Parkinson’s disease was typically modeled by chemical ablation of dopaminergic neurons using 
neurotoxins specific for the DA system [95] such as MPTP or the pesticide rotenone. Only in the 
last few decades, genetic models for the disease arose and became available. Not surprisingly, 
many models target Snca, as mutations in this gene are associated to familial PD and Snca is the 
principal component of Lewy bodies [96]. We have learnt, however, from these models 
[87,92,94,109,110,111] and from patients [2] that gene-dosage are primordial in the degree of 
mimicking or manifestation of the disease. Furthermore, genetic mouse models of Snca only 
partially recapitulate features of PD [94,111]. There is a consensus in the field that better models 
which more faithfully recapitulate PD are needed [78,81,96]. To that end, we sought to create a 
model more faithful in the expression level of Snca and in the spatio-temporal restriction of 
DAergic neurons affected in PD. This model would address in-vivo the neurotoxic effects of a 
synuclein variant that is structurally deficient to form aggregates. 
 
We designed a new model that included three key features of expression and that would separate 
it from previously existing ones. First, we cloned a floxed human wild-type SNCA into the 
endogenous Snca locus, thereby disrupting the mouse gene. Importantly, using the Snca 
endogenous promoter would ensure endogenous expression levels of the human SNCA variants 
encoded in our construct. Second, spatio-temporal regulation of expression specifically directed 
to DAergic neurons would be achieved by crossing our mice to the dopamine transporter-cre 
driver mouse line [112]. Third, this crossing also serves to drive a switch from wild-type to the 
mutant variant of synuclein carrying the triple-proline substitution (TP-SNCA). We propose that 
these features make our model a more refined and better one to study PD, specifically the toxicity 
of the TP-SNCA. This 2nd generation genetic model will also be useful in the testing and screening 





3.2.2. Validation of the model and investigation of TP-SNCA toxicity  
The new TP-SNCA PD model will be crossed to the DAT-cre driver line [112] and a stable colony 
will be established.  
 
Cre recombinase expression is driven by the DAT promoter and it mediates excision of wild-type 
SNCA and switching to TP-SNCA approximately at mid-embryonic day 15 [112]. Owing to TP-
SNCA’s higher toxicity, it would be likely to observe changes driven by its expression in the 
DAergic system of mice by early adulthood. For example, 3 to 4 month-old mice can be analyzed. 
This is an age well after all developmental processes have taken place. Mice of this age were also 
used by Bäckman and colleagues (creators of the DATcre line) to analyze selective deletion of 
PTEN in DAergic neurons [113] and by the Rubinstein group to analyze DA-D2 receptor ablation in 
DA neurons using the DATcre line [114]. In our case, behavioral testing will also help us define the 
age of onset of PD-like symptoms and thereby aid setting an ideal age to perform the molecular 
analysis.  
 
To prove that TP-SNCA is indeed produced in DAergic neurons, we will perform AP staining on 
coronal sections of adult mice. Then, histological staining of the brain will analyze its overall 
cytoarchitecture, especially in the DAergic regions, namely the SNpc and VTA. In-situ hybridization 
with tyrosine hydroxylase [115] will follow to mark and assess intactness of DAergic regions.  
 
DA is transported to the striatum along the nigrostriatal pathway and to limbic and cortical areas 
(e.g. the amygdala and cingulate cortex) along the mesolimbic and mesocortical pathways [82]. 
DA concentration in these areas will be measured by HPLC. Should TP-SNCA be more toxic, it 
would indeed follow that these areas be DA-depleted and the mice have motor PD-like symptoms. 
This rational is in keeping with the clinical scenario observed in PD patients [78]. 
 
To validate our model as one for PD, a full battery of behavioral tests will be performed. Tests 
focusing on motor dysfunction, as that seen in PD patients, will be of special interests. A first 
quality to be assessed in these mice is posture and gait, which can be detected by careful 
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observation and footprint patterns[116]. Motor tests such as the rotarod, the balance-beam test, 
the pulling-wire strength test and the hanging wire grip test will be included [116].  
 
Non-motor PD-like symptoms such as sleep and olfactory disorders are also of great relevance 
and should be studied [117]. For the former, mice will be placed into home cage running wheels 
to monitor their locomotor daily activity, preferably also including the complex running wheel 
with irregularly spaced crossbars [118] to challenge motor control and abilities of the mice. 
Actograms of activity will reveal whether circadian rhythms or sleep disturbances are present. To 
test olfactory disorders, an odor habituation test or an odor-based learning paradigm can be used 
[119]. 
 
To analyze the toxicity of TP-SNCA in more depth, we will survey the cellular responses elicited 
upon its toxic expression. We will perform immunohistochemistry using markers of neurotoxicity. 
Among others, we will include GFAP, CD11b, nitrotyrosine or the activation of the 
proteosome/ubiquitin system. 
 
Unfortunately, we still lack a direct detection system that distinguishes in-vivo Snca oligomers 
from fibrils from aggregates. However, structure-based analysis and in-vitro tests in lower 
organisms like C. elegans and Drosophila have already shown TP-SNCA’s inability to aggregate and 
its higher toxicity [100]. Our model would now build on those finding in assessing TP-SNCA’s 
toxicity in-vivo in a higher organism. These putative neurotoxic effects will certainly be identified 
and quantified by the methods described above. 
 
In conclusion, our model is not based on overexpression and the expression of the mutant SNCA 
will be spatio-temporal regulated. These key features make our model a suitable one to study the 
toxicity of TP-SNCA. We propose our model to be a more fine-tuned and specific model to study 
PD-like pathology. Additionally, our model will be an appropriate one to assess and validate 




Finally, the full value of our model relies on its potential to address toxic expression of SNCA in 
different cell populations. Our conditional floxed mice can be crossed with any cre-driver line to 
target expression of toxic SNCA to specific cell types or brain regions. For example, crossing our 
mice to the Th-cre driver line would direct toxic TP-SNCA expression to all catecholaminergic cells, 
including those of the LC. LC degeneration is also a well established feature of PD [34,43]. 





Chapter 4. Concluding remarks and future perspectives 
 
The new Ear2 (-/-)/APP/PS1 model of AD recapitulates more AD features. Notably, this model 
includes LC deficiency, an established early AD feature. This allowed us to study the contribution 
of LC deficiency to AD pathology. We found NA to be a modifying factor of AD and its deficiency 
aggravated AD pathology. NA deficiency seems to have a synergistic effect when in combination 
with APP/PS1; however, the exact mechanism by which NA facilitates AD-like phenotype is yet to 
be elucidated. To that end, we proved the hippocampal transcriptome of these mice and 
microarray data are now available. In situ hybridization and qPCR of the most deregulated genes 
will follow to validate microarray results. Follow-up studies seem to indicate that NA deficiency 
affects components of NMDA receptors and it has a role in the activation of learning-relevant 
genes. Specifically, we observe in Ear2 (-/-)/APP/PS1 mice a down-regulation of NR2A, an up-
regulation of NR2B and the phospho-activation of β-CamKII at Thr286.  
 
It will be interesting to analyze the global inflammation status and activation of the complement 
pathway in these mice in order to study the consequences of a chronic NA deficiency. Finally, 
these are a unique model to test potential therapeutic compounds aimed to remedy early 
features of AD.  
 
The TP-SNCA model will provide the unique opportunity to investigate the contribution of TP-
SNCA expression to PD pathology. This model will have spatio-temporal and dose-regulated 
expression of the toxic SNCA variant and it can be crossed to different cre driver lines to direct 
specific expression to desired target cell populations. It would be interesting, for example, to 
survey expression of TP-SNCA in frontal brain regions because damage in PD is preferential, but 
not restricted to, DAergic neurons. In such a case, a CamKIIcre line can be employed. This is 
already available in our lab. In addition, LC loss is also an established feature of PD and it would be 
interesting to cross the new TP-SNCA mice to LC-deficient Ear2 (-/-) mice to investigate the 
contribution of LC deficiency to PD pathology. 
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Chapter 5. Materials and Methods 
 
5.1 Animal experiments 
5.1.1 Animal housing and breeding 
All animal experiments were carried out in compliance with the German Law on Animal Welfare 
and were approved by the Office for Consumer Protection and Food Safety of the State of Lower 
Saxony. Mice were housed in transparent, individually ventilated cages (IVCs) with filter tops in 
specific pathogen free (SPF) conditions. Room temperature and humidity were held constant at 
21 °C and 55%, respectively, and animals were kept in a 12 hour light:12 hour dark cycle. Standard 
chow and water was provided ad libidium.  
 
Breeding was established either in pairs or triplets (2 females to one male) and not before the age 
of 8 weeks. Pups were weaned and ear-marked at the age of 3 weeks at which point 0.5 cm tail 
biopsies were taken for genotyping. All mice colonies, except for DATcre, were expanded and 
maintained through regular backcrosses to wild-type (wt) C57B/6N in order to maintain a rich 
genetic pool. DATcre was backcrossed to wt C57B/6J mice.  
 
Ear2 (-/-) mice were generated by replacing the two first coding exons of the Ear2 gene by an 
IRESLacZ/MC1neo cassette using the pKOS/Ear2-39 target vector [59]. The Ear2 mutation was 
brought into a pure C57B/6N genetic background by backcrossing Ear2 (+/-) mice of a mixed 
genetic background to wt C57B/6N mice for at least 8 generations before they were crossed to 
the APP/PS1 mice. Hemizygous double transgenic mice expressing a chimeric mouse/human APP 
with the Swedish mutation (K670N/M671L) and a mutant human PS1 with Δ exon 9 under the 
control of the prion protein promoter [120] were maintained on a C57BL/6N background. 
APP/PS1 mice were crossed to Ear2 KO (Ear2 (-/-)) mice and F1 progeny was interbred. To obtain 
Ear2 (-/-)/APP/PS1 and all pertinent controls, Ear2 (+/-) parents were mated with only one parent 
carrying APP/PS1 to ensure all progeny were hemizygous for the transgenes.  
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5.1.2 Behavioral paradigm – Morris water maze 
Mice were single-housed in the testing room under a reversed light/dark cycle (lights off at 8:00 
a.m., lights on at 8:00 p.m.) for at least two weeks prior to the beginning of experiments. Tests 
were performed during the dark phase, when mice are most active. Approximately equal numbers 
of male and female mice at the age of four months were used, prior to plaque deposition. As no 
significant differences between sexes were observed, data were combined. Behavior was scored 
by an observer blind to the genotype and treatment groups. 
 
The Morris water maze test was conducted in a pool consisting of a circular tank (diameter 1 m) 
filled with opacified water at 24 C. The water basin was dimly lit (20-30 lux) and surrounded by a 
white curtain. The maze was virtually divided into four segments (quadrants). In one of the 
quadrants, a hidden platform (15 x 15 cm) was present 1.5 cm below the water surface. Mice 
were trained to find the platform, orientating themselves by means of three intermaze cues 
placed asymmetrically as spatial references. To prevent strategy learning, they were let into the 
water in a quasi-random fashion. Mice were allowed to search for the platform for 40 sec. If the 
mice did not reach the platform in the allotted time, they were placed manually on it. The mice 
were allowed to stay on the platform for 15 sec before the next trial started. After four trials were 
completed, mice were dried and placed back into their home cage. Mice received 4 training trials 
per day for 8 consecutive days. Motion of the mice was recorded by a computerized tracking 
system that calculated distances swam and latencies (Noldus, The Netherlands). On the ninth day 
mice were tested for latency to find cued platform. 
 
 
5.1.3 Administration of drugs and treatment 
DOPS was generously provided by Dainippon-Sumitomo Pharmaceutical Company, Ltd. (Osaka, 
Japan). Ear2 (-/-) and Ear2 (-/-)/APP/PS1 mice were injected with either vehicle or DOPS solution. 
DOPS solution contained 500 mg/kg, s.c. DOPS, 125 mg/kg, s.c. benserizide, 2 mg/ml ascorbic acid 
– used to increase DOPS solubility. Benserazide is an inhibitor of the enzyme aromatic L-amino 
acid decarboxylase (AADC), which converts DOPS to NA. As benserizide cannot cross the blood-
brain barrier, DOPS + benserazide treatment restores NA levels to the brain selectively [74,106]. 
Ear2 (+/+), Ear2 (+/+)/APP/PS1 mice were treated with the corresponding volume of vehicle 
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solution. Mice were tested in the Morris water maze 5 hr after DOPS injection, when brain NA 
levels are reported to peak [74]. 
 
 
5.2 Histological methods 
5.2.1 Thioflavin S staining of frozen brain sections 
OCT-embedded (OCT, Tissue-Tek), fresh frozen 25 µm brain sections were used. Sections were 
fixed in 4% paraformaldehyde (PFA) for 25 min at room temperature, washed twice in 0.9 % NaCl 
for 2 min at room temperature and dehydrated through an ethanol gradient. Sections were 
stored until use at -20° in sealed boxes containing a desiccator bag. Thioflavin S staining was 
performed as previously described [121,122] with minor modifications. Briefly, sections were 
thawed and allowed to equilibrate to room temperature for at least 30 min. Sections were pre-
washed once briefly in 1x PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4 ) and 
then oxidized in 0.3% KMnO4 for 4 min and washed once with water. The bleaching solution 
consisted of 0.5% K2S2O5 and 0.5% oxalic acid. Sections were bleached until the brown color 
disappeared (approx 15 sec) and washed with water. A reduction treatment followed; this 
consisted of incubation in 1% NaBH4 solution for 5 min. NaBH4 solution was prepared fresh at 
least 2 hours before the experiment. Sections were washed 3 times in water and once in 1x PBS. A 
0.05% Thioflavin S solution in 50% ethanol was freshly prepared and sections were stained for 8 
min in the dark. Sections were differentiated twice in 80% for 10 sec each and rinsed 3 times with 
plenty of dist. water. A final incubation in a high concentration of phosphate buffer (411 mM 
NaCl, 8.1 mM KCl, 30 mM Na2HPO4, 5.2 mM KH2PO4, pH 7.2) was carried out at 4°C for at least 30 
min. Sections were briefly rinsed in dist. water and coverslipped using Vectashield Hard Set 
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5.3 Neurochemical determinations 
5.3.1 Noradrenaline quantification by HPLC – electrochemical analysis 
Concentration of NA was determined by HPLC with electrochemical detection as previously 
described with minor modifications [123,124]. Briefly, brains were dissected and washed in ice-
cold PBS. Specific brain regions were dissected on ice and immediately flash frozen in dry ice. For 
HPLC analysis, samples were weighed, homogenized in 100 (olfactory bulb, frontal cortex ), 200 
(hippocampus, cerebellum) or 300 (brain stem)µl sample buffer (0.1 M perchloric acid, 0.01% 
EDTA and 0.08 ng/µl 3,4-dihydroxybenzylamine – used as an internal standard) and subjected to 
two rounds of centrifugation (14 000 x g, 20 min each, 4 C). Immediately thereafter, 20 µl of the 
supernatant was injected into a C-18 reverse-phase column (Spherisorb ODS-I 5 µm, 250 x 4.6 
mm; Techlab). The isocratic mobile phase consisted of 0.15 M chloroacetic acid, 0.2 mM EDTA, 
0.86 mM sodium octyl sulfate, 6% acetonitrile and 2.5% tetrahydrofuran, pH 3. Flow rate was kept 
at 1.2 ml/min. NA was detected by an electrochemical detector (Coulochem II, model 5200A; esa, 
Chelmsford, MA, USA) and data was analyzed with the Clarity light software. 
 
 
5.4 Electrophysiology  
Electrophysiological recordings were performed on hippocampal brain slices from 4-month-old 
mice, obtained following anesthesia with isoflurane (5%) and decapitation. Brains were 
immediately dissected and sliced sagitally in 400 µm sections using a vibratome (Camden 
Instruments, Integraslice 7550 PSDS). Hippocampal slices were isolated and maintained at 29oC in 
an oxygen-enriched atmosphere in artificial cerebrospinal fluid (aCSF) (124 mM NaCl, 4mM KCl, 
1.24 mM NaH2PO4, 1.3 mM MgSO4, 26 mM NaHCO3, 10 mM D-glucose, and 1 mM CaCl2), for 30 
min, followed by incubation in aCSF at elevated CaCl2 (2 mM) for further 30 min. Single slices were 
moved to an interface-type recording chamber were they remained for additional 15 min. 
Extracellular field excitatory postsynaptic potentials (fEPSPs) were recorded in the pyramidal cell 
layer of the cornu ammonis 1 (CA1) region using glass microelectrodes (resistance 0.7 – 2 MΩ) 
filled with aCSF. The stimulating electrode was placed in the CA2 region within the Schaffer 
collaterals. Stimuli were applied at constant current, at a duration of 0.1 ms. The initial slope of 
evoked fEPSPs was measured as an index of synaptic strength. Basal synaptic transmission was 
assessed by plotting the stimulus intensity (mA) against the peak slope of the evoked fEPSP to 
generate input-output relations. Paired pulse facilitation (PPF) through two-stimulus protocols 
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with stimulus intervals of 30, 50, 75 and 100 ms at 30% maximal stimulation intensity. For long 
term potentiation (LTP) experiments, a 20 min baseline was recorded with an interpulse interval 
of 1 min at a stimulus intensity that evoked a response of approximately 30% of maximum fEPSP. 
LTP was induced by a theta burst consisting of 4 trains of 10 pulses at 100 Hz separated by 200 
ms. 
  
5.5 Molecular biology methods  
5.5.1 Conventional cloning 
All conventional cloning was performed using materials from New England Biolabs. High-fidelity 
enzymes were used when available. All protocols were carried out according to the 
manufacturer’s recommendations. All inserts generated by PCR were sub-cloned first into pGem®-
T Easy system (Promega) according to the manufacturer’s protocol. 
 
 
5.5.2 Mini preparations 
Mini preparations were performed using the NucleoSpin Extract II (Machery Nagel) and the 
QIAprep Spin Miniprep (Qiagen) kits.  
 
 
5.5.3 DNA purification for ES cell electroporation 
The sequence-verified pXL112 DTA SNCA to P3-neo targeting vector was linearized with the 
restriction enzyme SalI. Digestion efficiency was verified on a test-agarose gel and the linearized 
vector was phenol-chloroform extracted followed by nucleic-acid precipitation with 2 volumes of 
ethanol and 1/10 3 M NaAc. After two washes with ice-cold 70% ethanol, the DNA pellet was re-
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5.5.4 ES cell electroporation 
ES cell electroporation was performed by Sharif Mahsur (transgenic core facility, MPI-BPC). 1 µg 
linearized vector was electroporated into 129/SvPas embryonic stem (ES) cells. Clones were 
screened for integration of the transgene by G418 (Geneticin, neomycin analog) and resistant 
clones were grown in 24 well plates.  
 
5.5.5 ES cell DNA extraction  
To each well, 500 µl lysis buffer (10mM Tris-HCl pH 7.5, 10mM EDTA, 10mM NaCl, 1mg/ml 
proteinase K, 0.5% SDS) were added and 24-well plates were incubated overnight at 55°C. The 
following day, the contents of each well were transferred into a 1.5 ml microtube and 200 µl 
freshly prepared ice-cold NaCl/Ethanol mix (15 µl 5M NaCl per 1 ml cold 100% Ethanol) were 
added. After inverting several times, samples were centrifuged at 13000 rpm for 15 min at 4°C. 
The supernatant was discarded. After two washes with 700 µl 70% ethanol, the pellet was briefly 
allowed to air-dry and re-dissolved in 40 µl TE buffer. 
 
 
5.5.6 Southern blotting 
Overnight digestions (total volume = 50 µl) with BglII or BlpI restriction enzymes were set up and 
fragments were resolved on a 0.7% agarose gel over several hrs. Upon gel documentation under a 
UV-lamp, the ladder-containing lane was separated from the gel to avoid unspecific signal given 
by ladder fragments. The gel was incubated for 15 min in 4x volume of gel (typically 1 Lt) 0.2 N HCl 
(20 ml conc. HCl in 1 Lt water) with gentle shaking. This step eases the transfer of large DNA 
fragments to the blotting membrane. Two 20 min-denaturation washes followed in denaturing 
buffer (0.5 M NaOH, 1.5 M NaCl) with gentle shaking. For blotting, a small piece of Saran wrap 
was placed on the bench to contain the blotting sandwich. Two pre-cut sheets of Whatman filter 
paper were pre-wetted in denaturing buffer and carefully overlaid on top of the gel. Upon flipping 
(to have the gel on top), a pre-wetted in water and pre-equilibrated in denaturing buffer, 
HybondXL membrane (Amersham) was carefully laid on top avoiding bubbles. Two more pre-
wetted in denaturing buffer sheets of Whatman filter paper were place atop and a 10 ml pipette 
was gently rolled over to assure no bubble were present. Ends of the Saran wrap were folded in as 
to seal the sandwich to prevent contact from filter papers from the top and bottom. Paper towel 
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was stacked on top and a small bottle was placed atop to add light weight. DNA blotting was 
allowed overnight. On the following day, positions of the wells were marked onto the membrane 
and its upper, right corner was cut for orientation. The membrane was neutralized for 5 min in 
neutralizing buffer [500 ml NaPi (1 M NaPi, pH 6.7 stock)]. Blotting excess liquid off by placing the 
membrane in between two Whatman filter papers, the membrane was then UV crosslinked in 
Stratakinker (autocrosslinking setting, 1200J). 
 
The membrane was then shortly incubated at 65°C in pre-warmed Wash II buffer (1% SDS, 40 mM 
NaPi, pH 6.7) to equilibrate. 20 ml pre-warmed Church buffer (7% SDS, 300 mM NaPi pH 6.7, 5mM 
EDTA) were poured into a hybridization tube, the membrane was added and allowed to incubate 
at 65°C for at least 30 min. Meanwhile radioactive probes were generated from 35 ng PCR 
templates using the Rediprime™ II DNA Labeling System (GE Healthcare) and 32P labeled dCTPs 
(Easy Tides Deoxyciytidine 5-triphophate, Perkin Elmer) according the manufacturers’ procotols. 
Primers used to generate PCR templates were: BglII external probe forward primer 5’- 
AATGCACTCAGTTGAATTATTTC -3’ / BglII external probe reverse primer 5’- 
AATAGCATGGCATATGTGAATAATTC -3’; BlpI external probe forward primer 5’- 
TCCTGGGAGCAATTTGTTTATAG -3’ / BlpI external probe reverse primer 5’- 
ATTCCTATTCAAACCACCACAAC -3’. Radio-labelled probes were purified using the Illustra™ 
probequant G-50 micro colums (GE Healthcare) and heat-denatured (99°C, 5 min followed by 5 
min on ice). Hybridization was performed at 65°C overnight in 20 ml Church buffer. The following 
day, the membrane was washed 3x in Wash II buffer at 65°C, sealed in cling film and a Biomax MS 
film (Kodak) was exposed for several days at -80°C. 
 
 
5.5.7 ET cloning 
Single EL350 were picked from a LB plate (10g trypton, 5 g yeast extract, 10 g NaCl, 15 g agar to 1 
liter H2O) and 1.4 ml LB broth were inoculated and allowed to grow overnight at 32°C at 600 rpm 
shaking. 1.4 ml LB broth were inoculated with 40 µl of the overnight culture and allowed to grow 
for 3 hours at 32°C and 600 rpm shaking. Bacteria were made electro-competent by a short 
centrifugation step of 20 sec at 13 000 rpm at 4°C and 3 washes with ice-cold water. Electro-
competent bacteria were re-dissolved in 40 µl ice-cold ddH2O and 1 µl BAC bMQ-48E8 clones 
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(Geneservice Ltd.) was electroporated with 1.8 KV. 1 ml LB media was added, the culture was 
allowed to grow for 1 hr at 30°C with 300 rpm shaking. 50 and 100µl were plated on LB plates 
containing CAM (25µg/µl) and incubated overnight at 30°C. The following day, 1.4 ml LB with CAM 
were inoculated with a single clone and incubated overnight at 30°C with 600 rpm shaking. In 
parallel, vector pXL112-H1-H2 was digested with EcoRI and linearized vector was separated on an 
agarose gel overnight. The following day, 1 ml of overnight culture was used to inoculate 20 ml of 
LB broth with CAM and the culture was allowed to grow to an OD ~ 0.5 (2-3 hrs) at 32°C with 230 
rpm shaking. During this time, the linearized vector was gel extracted and eluted in 25 µl elution 
buffer. 10 ml of bacterial culture were transferred into a clean flask and ET-recombinase was 
induced by heat through a 15-min incubation at 42°C with shaking. The flask was immediately 
thereafter placed into wet-ice and allowed to incubate for 20 min. Contents were then 
transferred into a Falcon tube and spun at 5 000 rpm for 6 min at 4°C. Bacterial pellet was re-
suspended in 1ml ice-cold water, transferred into a microtube and bacteria were made electro-
competent as described above. 100 ng of linearized vector were electroporated and bacteria were 
allowed to grow. 50 and 100 µl culture were plated on LB with Amp (100 µg/µl) and incubated at 
32°C overnight. 10 clones were picked and analyzed via miniprep, PCR and restriction digest.  
 
All other ET cloning steps were carried out in a similar fashion using vectors and inserts as 
described in the text with appropriate antibiotic selection. 
 
 
5.5.8 DNA extraction from mouse tail biopsies 
Mouse tail biopsies of approx. 0.5 cm were digested overnight in 200 µl PBND buffer (50 mM KCl, 
10 mM Tris pH 8.3, 2.5 mM MgCl2, 0.1 mg/ml gelatin, 0.45% v/v NP40, 0.45% v/v Tween 20) plus 
3µl Proteinase K (20mg/ml, Roche) at 55°C with 750 rpm shaking. Proteinase K was heat-
denatured at 85°C for 1 hr with shaking and tail lysate allowed to cool at room temperature. After 
a pulse-spin centrifugation, 1 µl of tail extract was used for PCR reaction (Crude tail PCR, modified 
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5.5.9 Genotyping PCRs 
A PCR master mix was prepared for individual PCR reactions of 20 µl final volume. Specific primer 
sequences and PCR product sizes are provided in Table 1. The GoTaq Flexi DNA Polymerase 
(Promega) was used according to the manufacturer’s protocol. Primers were used at a 
concentration of 5 µM each. For the DATcre line, all 3 primers were added to the master mix and 
PCR products were analyzed in a 1% agarose gel. The PCR program consisted of an initial 
denaturing step (94°C) of 3 min, followed by 35 cycles of 94°C - 30 sec, 62°C - 1 min, 72°C – 30 sec. 
A final elongation step (72°C) of 7 min and a cooling step to 4°C were also programmed. For 
APP/PS1 either APP or PS1 primers were used in a PCR reaction using only 0.4 or 0.3 µl tail lysate, 
respectively. PCR conditions were as above except that cycles consisted of 94°C – 1 min, 65°C - 1 
min and 72°C – 45 sec. PCR primers detected the transgenes and samples were either positive or 
negative. PCR products were analyzed in a 1% agarose gel. For the Ear2 line, a 4-primer multiplex 
PCR reaction was set up and products were resolved on a 2 % agarose gel. PCR conditions were 
94°C – 4 min, 35x (94°C – 30 sec, 65°C – 30 sec, 72°C – 40 sec), 72°C – 7 min and 4°C – ever.  
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Line Primer name Primer sequence Product size 
DATcre IMR6625 com_fo 5'- TGG CTG TTG GTG TAA AGT GG -3' 
 
  IMR6626 wt_re 5'- GGA CAG GGA CAT GGT TGA CT -3' wt: 264 bp 




APP/PS1 PSEN1_fo 5'- GGT CCA CTT CGT ATG CTG -3' 
 
  PSEN1_re 5'- AAA CAA GCC CAA AGG TGA T -3' PS1: 500 bp 
  APP1597 5'- GAC TGA CCA CTC GAC CAG GTT CTG -3' 
 




Ear2 Ear2-nFo2 5'- GAC TCC ATG CAT AGC TGG TAC TTG G -3' 
 
  Ear2-nRe 5'- AGC ACT TCT TGA GCC GAC AGT ACT G -3' wt: 380 bp 
  LacZ_Fo 5'- CGT CAC ACT ACG TCT GAA CGT CG -3' 
 
  LacZ_Re 5'- CAG ACG ATT CAT TGG CAC CAT GC -3'  -/-: 400 bp 
 
Table 1. Genotyping primers and product sizes. 
 
 
5.5.10 Colorimetric in situ hybridization 
Automated in-situ hybridization procedures followed those described in Yaylaoglu et al. 2005 
[126,127]. These include tissue collection, sectioning, DNA template production, RNA probe 
synthesis and in-situ hybridization protocols. The following TH-specific (NM_009377) PCR primers 
were used: forward 5’-GATTGCAGAGATTGCCTTCC- 3’ and reverse 5’-CCTGTGGGTGGTACCCTATG-
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5.6 Statistical analysis 
All statistical evaluation was performed using the GraphPad Prism 5 software (San Diego, CA). 
Values were considered significantly different when p < 0.05. Data points and bars represent 
mean ± SEM in all figures unless otherwise indicated. *p  0.05; **p  0.01 and *** p  0.001. 
Behavioral data of the MWM test were analyzed by two-way ANOVA with repeated 
measurements (independent between subjects variables: APP/PS1 transgene, Ear2 (-/-) and DOPS 
treatment, dependent between subjects variables: latency or distance, independent within 
subject variable: day). All other experimental data were analyzed by two-way ANOVA if not stated 
otherwise. Bonferroni multiple comparisons post-tests were used. If a significant effect of the 
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AD Alzheimer's disease 
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HC Hippocampus 
IVC Individually ventilated cage 
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MCI Mild cognitive impairment 
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NA Noradrenaline 
OB Olfactory bulb 
ORF Open reading frame 
PD Parkinson's disease 
PS1 Presenilin 1 
SN Substantia nigra 
SPF Specific pathogen free 
Th Tyrosine hydroxylase 
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